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ABSTRACT
The renin-angiotensin system (RAS) is an endocrine system principally 
involved in the maintenance of cardiovascular homeostasis and electrolyte 
balance, its actions being mediated by the octapeptide hormone angiotensin II 
(ANGII).
In a preliminary observation we found marked activation of the RAS in acute 
severe asthma. The stimulus to this activation, and the possible consequences 
of elevated ANG II on lung function in man were unknown, although ANG II 
had recently been shown to potentiate bronchoconstriction of rabbit airway 
smooth muscle in vitro. The purpose of our investigation was to examine 
possible stimuli to ANG II release in acute asthma and also the direct and 
indirect effects of this hormone on airway function in vivo in man. Initial 
studies confirmed that single and multiple high doses of nebulised and also 
intravenous 8 2  agonists used in the treatment of asthma eg salbutamol, elevate 
ANG II levels in the plasma, but the levels achieved were less than those 
observed in acute severe asthma. Further studies revealed that hypoxia did not 
cause activation of the RAS in normal volunteers, nor did it potentiate the 
effect of nebulised 6 2  agonists. We also demonstrated that the elevation of 
ANG II levels by nebulised 8 2  agonists can be prevented by pretreatment with 
ACE inhibitor drugs (lisinopril), suggesting that this action of 8 2  agonists on 
the RAS is mediated via the classical components of the RAS, including ACE, 
rather than involving alternative pathways of ANG II generation.
When administered by intravenous infusion to produce similar plasma levels 
to those observed in acute asthma, ANG II caused bronchoconstriction in mild 
asthmatic patients, and in lower (subthreshold) doses potentiated the effect of 
inhaled methachoiine both in vitro in isolated human bronchi and also in vivo, 
in mild asthmatic patients. We therefore conclude from this series of 
experiments that the RAS is activated in acute severe asthma and that high 
dose 8 2  agonists are likely to be partly responsible for this activation. The role
of other possible stimuli, perhaps inflammatory mediators such as proteinase 
enzymes released from mast cells, remains to be established. Our findings also 
suggest a role for ANG II as a mediator in asthma, and further studies to 
examine the effects of ANG II receptor antagonists in different forms of 
experimental asthma are now indicated.
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CHAPTER 1
INTRODUCTION
1.1 THE PATHOGENESIS OF ASTHMA
Asthma is one of the most common medical disorders affecting over 5% of the 
adult population in the Western world and around 10% of children (1). There is 
evidence that morbidity and mortality from asthma is increasing in many 
countries, despite our increased understanding of its pathogenesis and advances in 
therapy. The American Thoracic Society defines asthma as “a clinical syndrome 
characterised by increased responsiveness of the tracheo-bronchial tree to a 
variety of stimuli. The major symptoms of asthma are paroxysms of dyspnoea, 
wheezing and cough, which may vary from mild and almost undetectable to 
severe and unremitting (status asthmaticus). The primary physiological 
manifestation of this hyperresponsiveness is variable airways obstruction, which 
can take the form of spontaneous fluctuations in the severity of obstruction 
following bronchodilators or corticosteroids, or increased obstruction caused by 
drugs or other stimuli” (2). Many attempts have been made to further classify 
asthma, the most commonly used being based on immunological status (atopic or 
non-atopic), as well as whether inhaled allergens provoke symptoms (extrinsic) or 
not (intrinsic). In addition, there is a category whose asthma is solely provoked by 
exercise (exercise-induced asthma).
One of the most characteristic features of asthma is the phenomenon of bronchial 
hyperresponsiveness (BHR), which is best described as an exaggerated 
bronchoconstrictor response to a variety of inhaled stimuli such as histamine, cold 
air or cholinergic agonists, eg methachoiine. Over the last 5 years or so it has 
become apparent that asthma is a chronic inflammatory disease of the bronchi in
which many cell types play a role, and that BHR is a likely to be a consequence 
of this inflammation. Thus, inflammatory changes in the bronchial mucosa are 
believed to play a fundamental part in the pathophysiology of asthma regardless 
of aetiology. Histological studies of the lungs of asthmatics who have died during 
aeute attacks show several common features with thickening of the bronchial wall 
due to hypertrophy of smooth muscle cells (3,4) and mucus plugging of the 
lumen. Inflammatory cells such as eosinophils and T lymphocytes are present, and 
the airway epithelium is often damaged with widespread shedding (5). By using 
the techniques of bronchial biopsy and bronchoalveolar lavage, similar, though 
less severe mucosal and submucosal abnormalities have been shown to be present 
in the lungs of even mild athmatic patients. Many different inflammatory 
mediators have been implicated in asthma although the exact role of each 
mediator in the pathophysiology of asthma is not yet clear, and the sequence of 
events which leads to asthmatic symptoms uncertain. The immediate stimulus is 
probably the release of mediators from a variety of inflammatory cells, which 
interact to cause the effects that are characteristic of asthma such as 
bronchoconstriction, mucus hypersecretion, bronchial oedema and plasma 
extravasation, as well as causing chemotaxis of other inflammatory cells.
1.1.1 Inflammatory cells
It is now clear that several different cell types may be involved in asthma, 
although the precise role of each is uncertain. Activation of mast cells is important 
in initiating immediate bronchoconstriction in response to allergen and other 
indirect stimuli such as exercise, cold air and hyperventilation (6 ). However it 
seems likely that in more chronic inflammatory events, including airway
hyperresponsiveness, other cells such as macrophages, eosinophils and T 
lymphocytes are more important. Macrophages are derived from blood monocytes 
and are activated in the airways in asthma by allergen combining with low affinity 
Ig E receptors on their surface. Dendritic cells, which are specialised macrophages 
in the airway epithelium, may then act as antigen presenting cells which process 
allergen for presentation to T-lymphocytes (7). They can also produce a large 
variety of proteins called cytokines which initiate an inflammatory response. 
Eosinophil infiltration is a characteristic feature of asthma, migrating into the 
airway in response to various chemotactic factors. Eosinophils were originally 
viewed as beneficial cells in asthma, but it is now more likely that they may play a 
damaging role via release of mediators which are cytotoxic for airway epithelial 
cells, for example basic proteins and oxygen-derived free radicals (8 ). The role of 
B lymphocytes in the synthesis of IgE is well documented, and more recently a 
role for T lymphocytes in asthma has also been recognised. T-lymphocytes are a 
feature of asthmatic airways and in particular, activated TH2 -iymphocytes may be 
involved in orchestrating the inflammatory response via the secretion of various 
cytokines such as IL-3, IL-4, IL-5 and GM-CSF. These products may in turn 
recruit eosinophils (9) and maintain the presence of mast cells in the airway (10). 
Platelets and neutrophils have also been implicated in asthma and the 
phenomenon of BHR but their exact role is uncertain.
1.1.2 Inflammatory mediators
For an inflammatory mediator to have a potential role in the pathogenesis of 
asthma, it must generally fulfill a number of criteria. When identified and 
administered (usually by inhalation) to asthmatic subjects it should mimic some 
component of the asthmatic response. The mediator, or a metabolite should be
4measurable in a biological fluid during the asthmatic response, it should be 
antagonised either by direct antagonists or inhibitors of its synthesis and most 
importantly it should be determined whether the mediator antagonists or synthesis 
inhibitors are of value in treating asthmatic patients. Many different mediators 
have been implicated in asthma and can produce several of the pathological 
features of asthma including bronchial smooth muscle contraction, mucus 
hypersecretion, microvascular leakage and inflamatory cell chemotaxis. Such 
mediators include histamine, prostaglandins, thromboxane, leukotrienes, 
bradykinin, platelet activating factor, and more recently cytokines and growth 
factors.
Histamine is formed within the mast cell or basophil and is rapidly metabolised 
in the tissues after release. Elevated levels of histamine may be detected in stable 
asthmatic subjects ( 1 1 ) and small rises have been described during allergen and 
exercise-induced bronchoconstriction ( 1 2 ). H i receptor antagonists have been 
reported to partially inhibit some asthmatic responses, for example, exercise (13) 
but even very potent and longer acting antihistamines are not effective 
bronchodilators nor do they have have a useful role in the management of asthma. 
Platelet activating factor (PAF) is released into the plasma following allergen 
challenge in mild asthmatic patients (14) and in normal subjects can cause 
bronchoconstriction and airway hyperresponsiveness when inhaled (15). PAF can 
recruit a variety of inflammatory cells including eosinophils and neutrophils and it 
was initially suggested that it may be an important mediator in allergen-induced 
asthmatic responses and in airway inflammation in asthma. However, recent 
potent antagonists have been shown to be ineffective in inhibiting allergen - 
induced asthmatic responses (16) or airway hyperresponsiveness (17) and oral
PAF antagonists have recently been shown to have no beneficial effect in chronic 
asthma (18). The role of high concentrations delivered by inhalation has not yet 
been established.
Prostaglandins PGD% and PGF2a  are released from human airways challenged 
with allergen (19) are potent bronchoconstrictors(20,21 ) and subthreshold 
contractile concentrations have been demonstrated to increase airway 
responsiveness to inhaled histamine and methachoiine in asthmatic subjects 
(22,23). Both PGD2  and PGF2 a  cause bronchoconstriction via a direct effect on
airway receptors and also indirectly  through cholinergic mediated 
bronchoconstriction (24). However specific receptor antagonists are not available 
to allow further characterisation of their importance in causing asthmatic 
responses. PGE2  and PGI2  are the only mediators with significant bronchodilator 
activity. There is evidence that manoevres that stimulate production of 
endogenously produced PGE2  protect against bronchoconstriction and recently it 
has been postulated that impaired production of PGE2  may contribute to the 
pathogenesis of asthma (25)
Leukotrienes LTC4  and LTD4  are the most potent bronchoconstrictor agents 
studied in humans, being up to 1 0 ,0 0 0  times more potent than methachoiine in 
some normal subjects (26). Increased urinary levels of ETE4 , the metabolite of 
LTC4  and LTD4  occurs after allergen-induced early responses and in patients 
with acute severe asthma (27,28). Initial studies with potent and specific 
leukotriene antagonists and synthesis inhibitors have demonstrated clinical 
efficacy in asthma (29).
Cytokines More than 30 different types of protein mediators or cytokines have 
been described. Examples include interleukin (IL)-3, IL-5 and granulocyte 
macrophage-colony stimulating factor (GM-CSF). They are produced by cells 
such as the helper T cell in asthmatic airways (30) and have the ability to promote 
eosinophil and mast cell differentiation and recruitment into the airways. GM- 
CSF is present in increases amounts in biopsies from asthmatic airways and levels 
increase after allergen challenge (31). It is likely that the cytokines play a 
dominant role in chronic inflammation, rather than the acute inflammatory 
response and further studies with specific antagonists are required to establish 
their precise role in the pathogenesis of asthma.
Endothelin-1 is a 21 amino-acid peptide which is a potent and long lasting 
constrictor of airway smooth muscle and bronchial vessels (32). It is expressed in 
airway epithelial cells in asthma (33) and raised concentrations of endothelin-1 
have been detected in bronchoalveolar lavage fluid from asthmatic patients (34). 
Accordingly, a role for this mediator is likely in asthma.
In summary, it is possible that a complex interaction between various 
inflammatory mediators might account for BHR, but at present the multiplicity of 
mediators makes it unlikely that antagonism of a single mediator will result in 
significant clinical improvement.
1.1.3 Airway smooth muscle
There is much debate about the role of abnormalities in airway smooth muscle 
activity in the pathogenesis of asthma and in the generation of BHR, and it is still 
not entirely clear whether an abnormality in airway smooth muscle itself, or in its 
control by nerves and mediators is responsible for the abnormalities of asthma. 
The exaggerated bronchoconstrictor response in asthma suggests some intrinsic 
abnormality of asthmatic airway smooth muscle, but studies of human airway 
contraction in vitro have failed to demonstrate any significant association with 
airway hyperresponsiveness in vivo (35-37). A small number of studies of 
airway smooth muscle from asthmatic subjects suggest that the smooth muscle is 
hyperresponsive to agonists in vitro when compared to airways from non­
asthmatic subjects (38,39) implying that there may be an inherent defect in 
asthmatic airway smooth muscle accounting for airway hyperresponsiveness.
In asthmatic airways, hypertrophy and hyperplasia of airway smooth muscle is 
evident, although the functional significance of this is uncertain. This may be the 
result of stimulation by growth factors released from inflammatory cells, or 
conversely, be a consequence of, rather than the cause of airway 
hyperresponsiveness. A recent study (40) raises the possibility that an increase in 
airway smooth m uscle volume in asthm atics m ight cause airway 
hyperresponsiveness by thickening of the airway wall. Using modelling studies it 
was demonstrated that a small increase in the thickness of the airway wall, 
undetectable by changes in spirom etry , could resu lt in airway 
hyperresponsiveness.
1.1.4 Neural mechanisms
Neural control of the human airway is complex and abnormalities of all 
components of the airway autonomic system have been suggested in the 
pathogenesis of asthma. Cholinergic nerves are the dominant neural 
bronchoconstrictor pathway, with the human airway being under continuous 
parasympathetic tone, as evident by the fact that anticholinergic drugs cause 
bronchodilation in asthmatic and non-asthmatic subjects (41).
In man, airway sensory receptors can be stimulated by the inhalation of histamine, 
cold air, sulphur dioxide and mechanical irritation, resulting in vagally mediated 
bronchoconstriction. Other postulated mechanisms which might contribute to 
cholinergic bronchoconstriction in asthma include increased central vagal drive, 
enhanced neurotransmission in cholinergic ganglia, either from release of other 
neurotransmitters or facilitation of acetylcholine release from postganglionic 
nerve terminals (42).
Adrenergic nerves do not control airway smooth muscle directly, and it is 
circulating catecholamines which play a more important role in regulation of 
bronchomotor tone. Several possible abnormalities in adrenergic control have 
been proposed in asthma (43) including enhanced a-adrenergic responses or 
defects in B-adrenergic responses, although presently these abnormalities are 
thought to be secondary to the disease rather than the primary cause. The role of 
non-adrenergic non-cholinergic (NANC) nerves in asthma remains uncertain, 
although neuropeptides which may act as neurotransmitters of NANC nerves have 
now been identified in human airways, eg nitric oxide and vasoactive intestinal 
peptide and are currently the subject of much research.
1.2 DRUG TREATMENT OF ASTHMA
Drugs used to treat asthma are conventionally divided into bronchodilator and 
prophylactic drugs. Examples of bronchodilator drugs include the 8 % agonists, 
anticholinergic agents and methylxanthines (eg theophylline), and prophylactic 
drugs are the corticosteroids and sodium cromoglycate.
1.2.1 Beta-2 (02) adrenoceptor agonists
Beta-2 agonists are the most effective and widely prescribed bronchodilators. 
They are particularly useful for mild episodic attacks of asthma, exercise-induced 
asthma and to supplement prophylactic agents in more severe cases. They are 
most effective when given by inhalation, as this delivers the drug directly to the 
site of action, maximising the bronchodilator effect and minimising generalised 
systemic effects. Examples include salbutamol (Ventolin®) and terbutaline 
(Bricanyl®), administered by aerosol. In acute attacks of asthma these drugs may 
be given by nebuliser, thus allowing greater drug delivery to the airways.
Mode of action
8  adrenoceptors are widely distributed in the lung and have been identified by 
autoradiography on airway epithelium, alveoli, submucosal glands and also on 
airway and vascular smooth muscle (44). The receptors on airway and vascular 
smooth muscle appear to be entirely of the 8 2  subtype, whereas 8 % receptors 
account for 10 - 30% of 8 - receptors on submucosal glands and alveolar walls. 8 2  
agonist drugs have several actions which affect airway function. They are potent 
bronchodilators by causing relaxation of bronchial smooth muscle (45) and 
therefore immediate relief of symptoms. Although their predominant effect is on
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bronchial smooth muscle, other actions include effects on some of the processes 
of acute inflammation, including suppression of inflammatory mediator release 
from mast cells (46) and possibly inhibition of vascular permeability and 
attenuation of inflammatory cell recruitment.
B agonists act through 13 adrenoceptors, activating the enzyme adenylate cyclase 
via a stimulatory guanine nucleotide regulatory protein (Gs). This enzyme 
catalyses the conversion of adenosine triphosphate (ATP) to adenosine 3 ‘5 ‘ 
monophosphate (cAMP). Intracellular cAMP is responsible for activation of 
specific protein kinases which, in bronchial smooth muscle, cause a reduction of 
phosphorylation of myosin light chain to reduce calcium-dependent coupling of 
actin and myosin and produce smooth muscle relaxation (47). 13 agonists also open 
potassium channels (maxi-K channels) in airway smooth muscle. This effect is 
observed at low concentrations of 13 agonists in vitro, suggesting that this may be a 
major mechanism of airway smooth muscle response to 13 agonists (48).
Cardiovascular and metabolic effects of 8 2  agonists
132 agonists cause vasodilatation, tachycardia and and increase in cardiac output 
(49). The latter effects have previously been attributed to reflex changes following 
peripheral vasodilatation, although recent work suggest that part of the response 
may be due to stimulation of cardiac 132 receptors. The metabolic and hormonal 
effects of 132 agonists include glycogenolysis, lipolysis and stimulation of renin, 
insulin, glucagon, parathyroid hormone and antidiuretic hormone (49). The 
decrease in serum potassium concentrations after 132 agonists is thought to be due 
to stimulation of membrane-bound Na/K ATPase activity, particularly in skeletal
11
muscle, rather than to insulin release. B agonists also cause an increase in 
physiological tremor, although this is rarely severe.
B2  agonists are widely prescribed and have been used for three decades as first 
line bronchodilator therapy in asthma. In general these drugs have a very high 
safety profile, however there is concern in a number of recent studies that regular 
use of B2  agonists is associated with increased morbidity and mortality from 
asthma. Inhaled fenoterol has been implicated as a possible contributing factor to 
the rise in asthma mortality in New Zealand since the late 1970's on the basis of a 
series of case-control studies (50-52). In addition, Sears et al showed that regular 
(as opposed to required) inhaled fenoterol resulted in a significant deterioration in 
disease control (53). A study of non-epidemic deaths in Saskatchewan noted a 
relationship between fatal and near fatal episodes of asthma and the regular use of 
B2  agonists (54), although it was unclear whether B agonists were directly 
responsible for these adverse effects or simply a marker for more severe asthma. 
More recently, Van Schayak noted a significant decline in lung function with 
regular inhaled bronchodilator drugs in general (55). The exact mechanisms 
whereby B2  agonists could have adverse efects on asthma mortality and morbidity 
are uncertain. Proposed theories have included hypokalaemia, cardiac 
dysrhythmias, tachyphylaxis (desensitisation) and exacerbation of airway hyper­
reactivity, but no satisfactory explanation has been provided. On present evidence 
it seems likely that the use of high dose and possibly less B2  selective preparations 
(eg fenoterol) were causally associated with increased mortality in the epidemics 
of asthma deaths. The studies of morbidity suggest that tolerance can occur to B2 
agonists in the form of a deterioration in asthma control, and it is recommended
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that patients receive the minimum doses of 8 2  agonist required once their inhaled 
steroid requirements are optimised.
1.2.2 Inhaled corticosteroids
These drugs represent a significant advance in the management of asthma. All 
patients who have persisting symptoms despite B2  agonist therapy require regular 
treatment with inhaled corticosteroids eg; beclomethasone, fluticasone or 
budesonide. Their exact mode of action is unknown but probably reflects their 
ability to directly inhibit inflammatory cells in the airway (56) thus reducing 
airway hyperresponsiveness. The main local side effects are candidiasis and 
dysphonia. Minor adrenal suppression and some systemic corticosteroid side 
effects may occur with higher doses.
1.2.3 Others
Other adjuncts include anticholinergic drugs eg inhaled ipratropium bromide 
(Atrovent), and oral theophylline preparations. High doses of oral corticosteroids 
eg prednisolone are often required for patients with severe exacerbations of 
asthma and lower doses for asthmatics who are not optimally controlled on 
inhaled therapy alone.
13
1.3 ACUTE SEVERE ASTHMA
Most acute severe attacks of asthma occur in patients whose asthma has been 
poorly controlled for days or weeks, although in some individuals, symptoms of 
asthma can develop rapidly, transforming the patient to a state of severe disability 
over a few hours or even minutes. Symptoms of an acute asthma attack include 
severe dyspnoea, chest tightness and often inability to complete sentences in one 
breath. Examination of the patient typically reveals a hyperinflated chest, rapid 
breathing and usually widespread wheeze on auscultation.
Useful indicators of a severe attack of asthma are a tachycardia greater than 1 10 
beats per minute and the most important respiratory signs of a severe attack arc a 
respiratory rate of 25 per minute or more, a silent chest and central cyanosis (57). 
Exhaustion and hypotension are serious signs indicating impending cardio­
respiratory failure. Arterial blood gas analysis is essential in the assesment of 
disease severity, and repeated measurements are necessary to monitor response to 
treatment. Most patients admitted to hospital with an exacerbation of asthma are 
hypoxaemic and about a third of patients admited with severe asthma have a Pa0 2  
of less than 8 kPa on air (58,59). Ventilatory function tests such as the peak 
expiratory flow rate (PEER) are of limited value in assessing the patient with 
acute severe asthma, but in general a PEER of < 33% predicted normal or best 
should be regarded as evidence of a potentially life threatening attack of asthma 
(60). Prolonged severe asthma can often lead to fluid deprivation, either from the 
breathless patient avoiding drinking or insensible loss from the respiratory tract 
and rarely intravenous fluids may be necessary for rehydration if the attack has 
been of several hours duration. Electrolyte imbalance such as hypokalaemia can 
also occur in some patients as a result of B2  agonist or corticosteroid therapy.
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If not recognised or treated appropriately, acute severe asthma may be fatal. Most 
asthmatic subjects admitted to hospital are hypoxaemic, and oxygen therapy 
should be administered as early as possible in the attack by face mask in the 
highest concentration available with the aim of raising the pa02 to above 8 kPa in 
all patients and preferably to between lOkPa and 14kPa in most patients (61). 
High doses of inhaled 8 2  agonists (eg salbutamol 5mg) are administered nebulised 
with oxygen, or if this is not available, by multiple actuations of a metered dose 
inhaler. High doses of systemic steroids are also recomended, for example 
prednisolone 30-60mg or intravenous hydrocortisone 200mg, or both. If life- 
threatening features are present, ipratropium bromide and intravenous 
aminophylline may be added. Recent guidelines on the management of acute 
asthma issued by the British Thoracic Society (60) recommend that if there is no 
improvement after 15-30 minutes, nebulised 8 2  agonists should be administered 
more frequently (up to every 15 minutes) and the use of parenteral 8 2  agonists (eg 
intravenous salbutamol) be considered. Patients with deteriorating peak flow rate, 
worsening hypoxia or hypercapnia, exhaustion or respiratory arrest merit 
subsequent admission to an intensive care unit to be considered for assisted 
ventilation.
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1.4 THE RENIN-ANGIOTENSIN SYSTEM
1.4.1 Historical background
The renin-angiotensin system (RAS) is an endocrine system which exerts its main 
physiological actions through a circulating effector peptide, angiotensin II (ANG
II) to regulate cardiovascular homeostasis and electrolyte balance. The hormone 
renin was first discovered in 1898 by Tigerstedt and Bergman in an elegant 
experiment where saline extracts of the renal cortex of rabbits were injected 
intravenously into anaesthetised rabbits. A rapid and significant rise in blood 
pressure was observed (62). This initial work failed to achieve full recognition 
until 1934, when Goldblatt and colleagues demonstrated that clamping of the 
renal arteries could produce hypertension (63), with renin later being successfully 
extracted and purified from the kidney. Soon afterwards, further studies revealed 
that in fact renin was not itself vasoconstrictor, but acted upon a substrate in the 
plasma to foiTu the vasoactive material which is now known as ANG II (64,65). A 
new dimension to the system was added in 1960 with the finding that ANG II 
stimulates the secretion of aldosterone, with consequent effects on salt and water 
balance.
1.4.2 The components of the renin-angiotensin system.
Since the discovery of renin nearly 100 years ago there have been major advances 
in our understanding of the RAS. The components of the RAS have now been 
identified and form a biological cascade (fig 1.1). The initiating enzyme of the 
system is renin, an aspartyl protease enzyme which is secreted into the circulation 
from the juxtaglomerular apparatus (JGA) in the afferent arteriole of the kidney. 
The JGA is an area adjacent to the segment of the distal convoluted tubule known
Angiotensinogen
Angiotensin I
t
Angiotensin II
[des-Asp] Angiotensin II 
("Angiotensin HI")
Inactive fragments
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Renin
Converting enzyme (ACE)
Aminopeptidase
Angiotensinases
Fig 1.1  Schematic diagram of the renin-angiotensin system and its biosynthetic 
pathways.
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as the macula densa. Release of renin is regulated by several mechanisms which 
will be reviewed later. Once released into the circulation, renin cleaves the large 
molecular weight (%2 globulin angiotensinogen to generate the inactive 
decapeptide angiotensin I (ANG I). The carboxy terminus of ANG I is then 
cleaved by angiotensin converting enzyme (ACE) to form ANG II. ACE is a 
membrane-bound dipeptidyl peptidase enzyme, present in vascular endothelium, 
with particularly high concentrations in the pulmonary circulation. Thus most 
activation of angiotensin occurs in the lungs. ACE has little substrate specificity 
also being involved in the processing of bradykinin, hence the alternative name of 
kininase. Although many studies suggest that ACE is the primary pathway leading 
to ANG II formation, alternative pathways have been proposed; ANG I has been 
shown to be rapidly converted to ANG II by neutrophil and mast cell proteinases 
(6 6 ) suggesting high local release of ANG II at inflammatory sites where both 
neutrophils and mast cells may be sequestered. In the failing human heart most 
ANG II can be formed by a pathway sensitive to a membrane-bound serine 
proteinase and not to an ACE inhibitor (67). Whether these alternative modes of 
ANG II generation are of clinical importance remains the focus of much debate. 
ANG II is the biologically active component through which the RAS exerts its 
effects. It has a short half-life (30 seconds) before undergoing further metabolism 
in the blood and other tissues to form the heptapeptide des-asp ANG II (or ANG
III). ANG III retains partial activity, being a weak pressor agent in comparison 
with ANG II. It appears to be of minor physiological importance as a circulating 
hormone, except in the brain where it may function as a neurotransmitter (6 8 ). 
Other smaller degradation products of ANG II and III are most likely inactive.
18
1.4.3 The control of renin seceretion
It is known that the release of renin is regulated by several mechanisms (fig 1.2) :
1 . A renal baroreceptor within the JGA which responds to changes 
in blood pressure in the afferent renal arteriole.
2. The macula densa which detects changes in the rate of delivery of sodium and / 
or chloride to the distal tubule.
3. A negative feedback of circulating angiotensin on renin secretion
4. The central nervous system via either the renal sympathetic nerves or 
circulating catecholamines.
Role of the sympathetic nervous system in the control of renin secretion.
The juxtaglom erular apparatus is densely innervated by postganglionic 
sympathetic nerves and stimulation of the renal nerves has been shown to 
increase renin secretion (69,70). Slices of renal tissue and cortical cell suspensions 
are also responsive to catecholamines indicating that renin release is due to a 
direct effect of these hormones on the juxtaglomerular cells rather than via 
alterations in renal haemodynamics (71).
Renin levels in the plasma are known to be increased in several situations where 
sympathetic activity is increased, including exercise (72), standing or tilting (73), 
hypoglycaemia (74) and non-hypotensive haemorrhage (74). It is now generally 
accepted that the direct effect of catecholamines on renin-secretion is mediated by 
B adrenoceptors as this effect can be blocked by the non-selective B antagonist 
propranolol (75), Although autoradiography has demonstrated that the B receptors 
on the juxtaglomerular cells in the dog, rat and guinea-pig are B] in nature (76- 
78), the B adrenoceptor subtype involved in renin release in man has been the
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Fig 1.2 Mechanisms for the release of renin from juxtaglomerular cells of the 
kidney. From ref (79).
1. beta- 1 sympathetic activity
2 . hypotension or decreased renal blood flow
3 . decreased tubular reabsorption of sodium eg; during a low sodium diet or 
diuretic therapy.
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subject of much controversy. On the basis of pharmacological evidence it is now 
generally believed that the B i adrenergic receptor is probably the predominant 
subtype involved. This is supported by the observation that pretreatment of 
volunteers with the selective B i antagonists atenolol, metoprolol or acebutolol 
prevents the rise in renin produced by isoprenaline (a non-selective B agonist) as 
effectively as propranolol (a non-selective B antagonist)(80,81).
When selective B agonists are studied however, the results are conflicting, and the 
evidence for B) mediated release of renin in man becomes less conclusive. 
Selective B2  agonists eg salbutamol, stimulate renin release in some studies 
(82,83) but not in others (84,85). It remains unclear whether the effect of B2 
agonists on plasma renin is, in fact, a result of their ability to cause hypokalaemia, 
to increase plasma noradrenaline levels or perhaps by a partial agonist effect on 
Bi receptors, rather than a direct interaction with juxtaglomerular B2  receptors. 
Studies of the effect of selective B l agonists on renin release has also produced 
conflicting results (8 6 -8 8 ). The reason for this is unclear but may be due to 
activation of mechanisms that actually inhibit sympathetic stimulation of renin 
release eg the positive inotropic, chronotropic and pressor actions of the Bi 
agonists.
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Other factors influencing renin secretion
Many other physiological and pharmacological stimuli can influence the activity 
of the RAS in man and an awareness of these is important prior to interpreting 
changes in circulating levels of renin and ANG II;
1. Electrolyte and water intake - a low dietary sodium (89), dehydration and to a 
lesser extent potassium depletion (90) stimulates the RAS.
2. Haemorrhage - bleeding is a marked stimulus to renin secretion, particularly 
when associated with hypotension and hypovolaemia (91).
3. Arterial pressure - in normal subjects and those with essential hypertension, 
there appears to be no relationship, or an inverse relationship between blood 
pressure and plasma renin. However, in experimental and clinical renovascular 
hypertension there is a clear positive correlation between ANG II and blood 
pressure (92,93).
4. Diurnal changes - a modest variation in plasma renin concentration occurs 
during a 24 hour period with a peak at 1000 and a trough at 2200 (94).
5. Age, gender and race - there is a progressive fall in renin with age, plasma renin 
activity is lower in women than age-matched men and Negroes have been found 
to have lower plasma renin activity than Caucasians (95).
6 . Cigarette smoking - mean plasma renin activity has been found to be 
approximately 20% higher in smokers than non-smokers (95).
7. Drugs - diuretic agents such as thiazides (96) and loop diuretics (97) increase 
renin as a result of their natriuretic and potassium losing effects. Other drugs 
reported to increase renin include lithium (98) and calcium antagonists (99). Non­
steroidal anti-inflammatory drugs eg indomethacin have been reported to reduce 
plasma renin activity after single or multiple doses ( 1 0 0 ).
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1.4.4 ANGIOTENSIN II 
Acute effects
Angiotensin II (ANG II) is an octapeptide hormone with several important 
physiological actions. The first of these to be identified was its pressor action 
( 1 0 1 ), and for many years it was believed that the main role of the RAS was to 
regulate blood presssure. ANG II can rapidly raise the blood pressure by several 
mechanisms (102) : It may act directly on specific angiotensin receptor sites on 
the vascular wall to cause vasoconstriction. In addition ANG II has a facilitatory 
role on the sympathetic nervous system, enhancing the release of noradrenaline 
from adrenergic vasoconstrictor nerves by stimulation of presynaptic angiotensin 
receptors. This action is independent of its direct effect on the vascular receptor. 
ANG II can also cause vasoconstriction by potentiating catecholamine release 
from the adrenal medulla.
Besides acting as a vasoconstrictor, ANG II stimulates the secretion of the 
sodium-retaining hormone aldosterone from the zona glomerulosa of the adrenal 
cortex (102). The action of aldosterone is to increase sodium reabsorption from 
urine, sweat, saliva and gastointestinal secretions. By promoting sodium and 
water reabsorption at the distal tubule and collecting duct of the kidney, 
aldosterone increases potassium and hydrogen-ion secretion, thus maintaining 
extracellular fluid volume and acid-base balance. The RAS is the chief regulator 
of aldosterone in states of volume depletion.
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ANG II as a growth factor
In addition to its acute effects on aldosterone secretion and vasoconstriction, ANG 
II exerts long term effects on cellular regulation and growth. Recent in vitro 
studies have demonstrated that ANG II has a direct hypertrophic effect on cardiac 
myocytes (103), and ANG II has been reported to stimulate the growth of cultured 
human smooth muscle cells in vitro (104). The intracellular pathways mediating 
this effect are the subject of current research although second messengers related 
to the activation of protein kinase C are known to be involved (105). Although 
there is little direct evidence for such an effect in vivo, local generation of ANG II 
in the heart and vascular wall may play a role in causing vascular and cardiac 
hypertrophy. Such changes may be important in the long term, either by causing 
increased vascular resistance in hypertension or left ventricular hypertrophy, a 
risk factor for cardiovascular mortality.
Angiotensin II receptors and intracellular messenger systems
The effects of ANG II are now known to be mediated by its interaction with 
specific, high affinity receptors on the plasma membrane of its target cells. 
Recently, the development of highly selective ANG II receptor ligands has led to 
the identification and characterisation of these receptors in a number of tissues, 
including vascular smooth muscle, heart, uterus, the adrenal zona glomerulosa and 
the brain (106). The receptors are coupled to cellular activation by a variety of 
biochemical signalling systems which include guanyl nucleotide regulatory 
proteins (G proteins), membrane enzymes and ion channels. Two receptor 
subtypes termed ATj and AT2 have recently been described.
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The AT 1 receptor mediates all or most of the known biochemical and 
physiological actions of ANG II, including contraction of smooth muscle and 
aldosterone production. ATi is a membrane linked protein which transmits ANG 
II activity via a G-protein linked pathway. Two G proteins are known to be 
associated with the AT i receptor, the major of which (Gq) is coupled to a 
phosphodiesterase enzyme known as phopholipase C, and the other (Gi) to the 
inhibition of adenylate cyclase. Most of the known actions of ANG II are exerted 
through receptor-mediated hydrolysis of inositol phospholipids and increased 
cytoplasmic calcium levels via the Gq protein (108,109). The primary event is the 
cleavage by phospholipase C of phophatidylinositol 4, 5 bisphosphate 
(PtdIns(4 ,5 )P2 ) to form Ins (l,4,5)Pg and sn-1,2 diacyl glycerol. These products 
subsequently act as intracellular second messengers to mediate hormone action 
(79). IP3  liberates calcium from the intracellular sarcoplasmic reticulum whereas 
diacyl glycerol activates protein kinase C, which is thought to act on contractile 
proteins to produce a sustained response. When vascular angiotensin receptors are 
activated it is believed that two mechanisms lead to an increased release of 
calcium from the sarcoplasmic reticulum (79). Firstly the formation of IP3 and 
secondly via an additional direct G-protein mediated stimulation of a calcium 
channel. The resultant release of calcium increases vascular contraction and tone. 
Similarly, the cellular mechanisms whereby ANG II stimulates aldosterone 
release from the adrenal zona glomerulosa are also thought to be initiated b\ a 
receptor-mediated rise in cytoplasmic calcium concentration. This effect, in 
conjunction with protein kinase C produces phosphorylation of key enzymes 
involved in the conversion of stored cholesterol and corticosterone to aldosterone 
in the cells of the adrenal zona glomerulosa ( 1 1 0 ).
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The AT 1 receptor subtype is sensitive to the nonpeptide antagonist losartin, a drug 
which has been shown to have potent inhibitory effects on ANG II induced 
vasoconstriction in animal studies. Being orally active, drugs such as losartin are 
currently being introduced in the management of certain forms of hypertension.
In contrast, AT2 receptors do not appear to be coupled to G-proteins and as yet 
there is little evidence for a functional role of this subtype. However their recent 
identification in the foetal and immature brain and subcutaneous tissues suggests a 
possible role for these receptors in mediating developmental actions of ANG II 
( 111).
1.4.5 Local renin-angiotensin systems
Although many of the actions of the RAS are typical of an endocrine system, 
where the effects are mediated entirely by circulating hormones, there is now 
evidence to suggest that the components of the RAS are also present and 
functional in a number of tissues including blood vessels, heart and brain. Such 
local or tissue RAS’s are believed to have a local or paracrine role, probably being 
responsible for the maintenance of vascular structure and the long term control of 
blood pressure, in contrast to the plasma RAS which has a more acute regulatory 
role. The brain RAS is one of the most studied tissue RAS (112), and the 
components of the system have been localised in many areas of the brain thought 
to be involved in cardiovascular regulation such as the hypothalamus and 
medulla. There is currently considerable evidence that the brain RAS plays a role 
in the development or maintenance of hypertension, with ANG II acting as a 
neurotransmitter or neuromodulator. Results from other studies suggest that a 
local renin-angiotensin system also exists in the heart ; cardiac myocytes and 
isolated perfused rat hearts are known to produce renin and ANG II (113), and
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ACE activity has been detected in the atria and ventricles of rat hearts (113). It has 
been proposed that ANG II produced locally by the myocardium may have 
important physiological and pathological functions eg ventricular remodelling and 
compensatory hypertrophy after myocardial infarction. Similarly, local generation 
of ANG II in blood vessels may play a role in the modulation of vascular tone, 
and interference with the intrinsic RAS in the blood vessels could contribute to 
the fall in blood pressure with ACE inhibitor treatment.
The potential functions of these and other tissue RAS eg; the reproductive tract 
and kidney are at present a rapidly developing and exciting area of research.
1.4.6 Inhibitors of the renin-angiotensin system
Angiotensin converting enzyme is a zinc dependent metallo-peptidase enzyme. 
The first ACE inhibitor agent to be discovered in 1977, captopril, incorporated a 
sulfhydryl group to bind to the zinc (114). Subsequent ACE inhibitors have been 
developed with alternative zinc ligands, better potency or longer durations of 
action. All the ACE inhibitor drugs block the enzyme both in the plasma and in 
the tissues, although the degree of inhibition varies with different inhibitors (115). 
Orally active ACE inhibitor drugs eg; captopril and lisinopril, are now established 
therapy in two of the most common cardiovascular conditions, hypertension and 
congestive cardiac failure. In the treatment of hypertension, several mechanisms 
may be involved; The main acute effect is clearly to decrease circulating ANG II 
levels and thus cause vasodilatation with another possible major site of action 
being the tissue RAS, including ACE activity in the vascular bed. Other 
postulated mechanisms include increased formation of bradykinins or 
prostaglandins with vasodilatating properties (116), modulation of adrenergic
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activity (117) eg; by inhibiting noradrenaline release from adrenergic nerves, or 
by causing natriuresis (118). Extensive studies have also demonstrated the 
benefits of acute and chronic use of ACE inhibitors in congestive heart failure. 
They have been shown to relieve symptoms and improve exercise tolerance, and 
in addition, delay the progression of left ventricular dysfunction after myocardial 
infarction (119) and to reduce mortality in moderate to severe heart failure 
( 120, 121).
The recent development of non-peptide (and hence orally active) specific ANC II 
antagonists eg losartan, offers the possibility of long term blockade of the A1 i 
receptor. Although preliminary observations in hypertension are encouraging, it 
remains to be seen how effective these drugs will be in the long term.
1.4.7 Genetic aspects of the RAS : the ACE genotype
A polymorphic marker which correlates with circulating ACE levels has recenti} 
been identified in the ACE gene. Posession of this marker (D) (deletion of a 287 
base pair) has been shown to be a risk factor for coronary artery disease ( 1 2 2 ), 
particularly in men otherwise considered to be at low risk. DD genotype is 
associated with higher levels of circulating ACE in these patients, and is 
significantly more frequent in people who have had a myocardial infarction than 
in age matched controls. The DD genotype frequency has also been shown to be a 
risk factor for the development of end-stage heart failure due to cardiomyopathy 
(123), and it is proposed that molecular variants in ACE may, by altering local 
cardiac ANG 11 levels, influence ventricular structure and function, via the trophic 
effect of ANG 11 on cardiac myocytes.
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1.5 THE RENIN-ANGIOTENSIN SYSTEM IN ASTHMA :
BACKGROUND TO CURRENT STUDIES,
Activation of the RAS has been described in a variety of pathophysiological states 
in man including myocardial infarction (124), acute renal failure (125) and severe 
haemorrhage (91). However, the activity of the RAS in asthma has not been 
previously described, and the direct effect of ANG II on bronchomotor tone is 
unknown. In a preliminary study in which we measured hormonal influences in 
patients with acute severe asthma, marked activation of the RAS was noted. The 
stimulus to this activation, and the possible significance of the effects of elevated 
plasma levels of ANG II in asthma was unclear.
A subsequent search of the relevant literature revealed that ANG II could 
potentiate contraction of rabbit airway smooth muscle in vitro (126), thus raising 
the possibility that this hormone may possess bronchoconstrictor activity in vivo. 
Intrigued by our initial observations in acute asthma, we then decided to confirm 
and extend this preliminary observation in a larger number of patients.
Possible stimuli which could potentially cause activation of the RAS in acute 
severe asthma include hypoxia (127,128), 132 agonists (129,82), circulating 
catecholamines (130) and inflammatory mediators (131,66) and the contribution 
of some of these stimuli was investigated in subsequent studies in this thesis. The 
effect of 132 agonists were of particular interest in view of the current concerns 
over the safety of these agents in asthma (50-54).
Although the effects of elevations of ANG II on pulmonary function are unclear, 
ANG II could, in theory, adversely affect the lungs by several mechanisms, 
including bronchoconstriction (126). The remainder of the studies were designed
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to examine the direct and indirect effects of ANG II on airway function in vivo in 
mild asthmatic patients, and also in vitro on human airway smooth muscle.
The results of these investigations should increase our understanding of the role of 
ANG II on airway function in asthma, and in particular will allow us to establish 
whether the elevated levels of ANG II in acute severe asthma have an adverse 
effect on lung function. These results will hopefully clarify some of the 
pathophysiological processes occurring in acute severe asthma and in addition 
determine whether ANG II might be a mediator in asthma.
CHAPTER 2
GENERAL METHODS AND MEASUREMENTS
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2.1 SUBJECTS
Patients presenting with acute severe asthma were identified at the Accident and 
Emergency Unit of the Western Infirmary and respiratory wards at Gartnavel 
General Hospital, Glasgow. Mild asthmatic subjects were recruited from 
outpatient asthma and general respiratory clinics at Gartnavel General Hospital, 
the Western Infirmary, Glasgow and Dumbarton Health Centre. Healthy 
volunteers were comprised mainly of nursing, medical and secretarial staff in 
these hospitals. None of the asthmatic subjects or healthy volunteers were 
smokers. Further demographic data for each subject group is discussed in the 
appropriate chapter.
2.2 LUNG FUNCTION
Peak expiratory flow rate (PEFR), as measured by a mini W right’s peak flow 
meter, provides a simple measurement of airflow obstruction and is often used 
for the home monitoring of asthma. In addition, this test forms part of the 
assessment of acutely ill patients presenting to hospital with severe asthma.
In all cases the PEFR was recorded as the best of 3 readings (unless otherwise 
stated).
Spirometry is performed using a dry wedge spirometer (Vitalograph-S) or 
portable pneumotachograph spirometer (Vitalograph-Compact), both from 
Vitalograph, Buckinghamshire, UK, the machines being calibrated prior to each 
study. The most common measurement to determine limitation to airflow is the 
volume expired in the first second (FEV} or forced expiratory volume in the first
31
second of expiration), in general values below 70% predicted for age (132) 
indicating airflow obstruction. However mild asthmatic subjects (as in the present 
study) often have FEVi values in excess of this. For all studies the best of 3 
readings was recorded.
2.3 METHACHOLINE CHALLENGE (PROVOCATION TEST)
A number of different agents have been used to demonstrate bronchial 
hyperreactivity in asthma, methacholine and histamine being the most common 
and reliable of the non-specific bronchoconstrictors. These agents can also 
produce airway narrowing in normal subjects, but at much higher doses than those 
affecting asthmatic patients. Methacholine responsiveness is affected by asthma 
medication and this should be taken into account prior to testing. Tests were 
performed at the same time of day for each subject.
Short acting 132 agonists (eg; Salbutamol) were withheld for 8  hours, long acting 
132 agonists (eg; Salmeterol) were withheld for 24 hours and slow release 
theophylline preparations were withheld for 48 hours before the test. Inhaled 
corticosteroids continued unchanged. The method of mesurement of bronchial 
reactivity to methacholine used a method described by Cockroft (133) and 
Hargreave (134). Aerosols were generated using the same Wright nebuliser and 
delivered through a loose fitting facemask. Subjects wore a noseclip and inhaled 
the aerosol through the mouth by normal tidal breathing. The nebuliser contained 
a volume of 3ml of solution and was driven by a continuous airflow at 81/min 
from a compressed air source of 50 lbs/in (345 kPa) giving an output of 
approximately 0.15ml/min. Baseline FEV i was measured as previously described 
and until reproducible within 5%. Subjects than inhaled phosphate buffered saline
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for 2 minutes and FEV l recorded again at 30, 90 and 180 seconds. The lowest 
post-saline value was then used as the baseline from which subsequent falls were 
measured. At 5 minute intervals, subjects received doubling concentrations of 
methacholine (0.0625mg to 8 mg/ml) and FEV i repeated at 30, 90 and 180 
seconds. Inhalations were continued until the FEV i fell by 20% or more from the 
lowest post-saline value. Results were then expressed as the PC20 (provocation 
concentration 2 0 %), which was calculated by linear interpolation of the dose- 
response curve for each individual. All mild asthmatic subjects in the present 
study demonstrated at least mild hyperresponsiveness to methacholine with a 
PC20 < 8 mg/ml. The value for normal individuals is > 8 mg/ml.
At the end of each methacholine challenge, subjects received nebulised 
salbutamol to reverse the bronchoconstriction.
2.4 HORMONE ASSAYS
Hormone assays were performed by Dr JJ Morton in the Blood Pressure Unit, 
Western Infirmary, Glasgow. Accuracy of ANG II measurement has improved 
over the last decade and sample handling bias has become appreciated. Since 
ANG II can be generated in the plasma after blood sampling, it is therefore 
neceassary to ensure that samples are collected into prechilled tubes containing 
inhibitor cocktails, with rapid centrifugation and quick freezing of the plasma 
thereafter. Other pitfalls of blood sampling for both renin and ANG II 
measurement are the effects of factors such as posture, diurnal variation, 
concurrent medication and food intake (chapter 1.4.3).
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As measurement of plasma renin and ANG II levels in asthma and healthy 
volunteers constitutes an important aspect of the methods used in this thesis, a 
more extensive description of the assays for these particular hormones is included.
Angiotensin II
7 mls venous blood was collected rapidly into an iced glass sample tube containing 
1ml EOT A / o-phenanthroline to inhibit angiotensin converting enzyme and 
angiotensinase enzymes. After thorough mixing, samples were immediately 
centrifuged at 3000rpm for 10  minutes at 4^'C and plasma stored at -20'* C pending 
hormone analysis.
The assay for ANG II is a modified radioimmunoassay originally developed by 
Dusterdieck and McElwee (135) with modifications by Morton and Webb (136). 
ANG II was extracted from the plasma using Sep-Pak C18 cartidges pretreated 
with methanol (5mls) and water (5mis). After washing with water ANG II was 
eluted from the column with 80% methanol (2mls). The extracts were dried under 
a stream of air and redissolved in 4000pl of Tris Buffer for assay. Radiolabelled 
ANG II and ANG II antibodies were added to tubes containing lOOpl of sample 
and a standard curve made up using dilutions from lOOpg to 1.56pg unlabelled 
ANG II per tube. All the tubes were then incubated at 4^C for 18 hours. I ml of 
dextran-coated charcoal was then added to separate unbound ANG II and mixed 
thoroughly before centrifugation at 3000rpm for 7 minutes. The supernatant was 
removed and the residue counted for 100 seconds in a gamma counter (Nuclear 
Enterprises NE 1612). Calculation of ANG II levels was performed automatically 
by an on-line computer. Recovery from plasma is >95%. The intra-assay 
coefficient of variation is 6.4% and inter-assay variation 10%.
The normal reference range for our laboratory is 3-12pg/ml.
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Renin
5ml venous blood was collected into potassium EDTA tubes and kept at room 
temperature. Plasma was separated by centrifugation at 3000rpm for 10 minutes 
at 4 0 c  and samples stored at -2CPC until assay. The assay for renin is based on the 
method developed by M illar et al (137) which measures plasma renin 
concentration rather than plasma renin activity, and is based on antibody trapping. 
This assay is capable of determining concentrations of both total and active renin. 
For the active renin assay 20pi of plasma was added to a standard mixture 
containing purified ox renin substrate, Tris buffer and antibody to ANG I and the 
mixture incubated at 37° C for 30 minutes. Active renin within plasma converts 
renin substrate to ANG I which is bound by the antibody. The reaction is stopped 
by the addition of cold Tris buffer. A standard curve is then derived by adding 
serial dilutions of ANG I standard to the mixture, and blank tubes with no ANG I 
and empty tubes for total counts also included. Labelled ANG I was then added to 
all the tubes and incubated at 4° C for 18 hours. Free and bound ligand were 
separated by the addition of 1 ml of dextran coated charcoal and free ligand was 
counted in a gamma counter (Nuclear Enterprises NE 1612) for 100 seconds and 
the results computed automatically.
The intra-assay range for active renin is 5.5% and inter-assay range 11%.
Our normal laboratory reference range for active renin is 9-50 pU/ml.
Catecholamines
5mls of venous blood were collected into chilled lithium heparin tubes and kept 
on ice until centrifugation at 4° C. Plasma noradrenaline and adrenaline were then 
measured by reverse phase high performance liquid chromatography and
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electrochemical detection after extraction from plasma using activated alumina as 
described by Goldstein et al (138). The coefficient of variation is less than 10% 
and normal values are < 5.0 nmol/1 and < 0.4 nmol / 1 for noradrenaline and 
adrenaline respectively.
ACE (Angiotensin Converting Enzyme)
Measurement of serum ACE employs a continuous spectrophotometric method 
based on the hydrolysis of furylacrylpenylalanineglycylglycine (FAPGG) and 
applied to an IL Multistat II centrifugal analyser. The method is that described by 
Maguire and Price ( 139).
The reference range for our laboratory is 20-95U/L.
2.5 ARTERIAL BLOOD GASES
Arterial blood gases (ABG's) were sampled on air from the radial artery using a 
pulsator blood sampling system (Concord laboratories) and analysed using a 
Ciba-Coming 288 blood gas system.
Normal values are Pa02 1 l-13kPa and PaC02 4.5-6kPa.
2.6 HAEMATOCRIT (or PACKED RED CELL VOLUME) 
Measured by an automated Coulter Counter.
Normal values are 0.4 -0.541/1 (males) and 0.37-0.47 1/1 (females)
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2.7 24 HOUR URINARY SODIUM
This was measured using diluting ion selective electrodes (Olympus 5200 
analyser).
The normal reference range is 100-250mmol / 24hr
2.8 DRUGS
Angiotensin II (Hypertensin®, Sigma Chemical Company, Poole, Dorset, UK) 
kindly donated by Dr A. Morris, University Department of Medicine and 
Therapeutics, Western Infirmary, Glasgow. Angiotensin II was prepared in 5% 
dextrose as a solution for intravenous infusion.
Methacholine for inhalational challenge (acetyl-B-methyl choline chloride, Sigma 
Chemical Company, Poole, Dorset, UK) made up in phosphate buffered saline to 
pH 7.4.
Salbutamol (Ventolin ®) solution for nébulisation 5mg prepared in 3.5 ml normal 
(0.9%) saline.
Fenotero! (Berotec®) solution for nébulisation 2.5mg prepared in 3.5ml normal 
saline.
Lisinopril (2 0 mg) and identical placebo capsules prepared in the hospital 
pharmacy sterile unit.
For the in vitro studies methacholine and angiotensin II were supplied from 
Sigma Chemicals, Poole, Dorset, and prepared in distilled water with serial 
dilutions in Krebs-Henseleit solution.
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2.9 STATISTICAL ANALYSIS
Statistical analysis was performed on an Apple Macintosh LC II computer using 
the Statview® software package.
In the acute asthma study (Chapter 3) differences in plasma renin and ANG 11 
levels between the different groups of asthmatic patients and control subjects was 
evaluated using the Mann-Whitney U-test, and the absolute numbers of patients 
with elevated plasma renin and ANG II levels within each group was compared 
using the X  ^ test, p values below 0.05 were accepted as significant.
For the studies outlined in Chapters 4 to 8, comparison of baseline levels and the 
significance of changes in these at each time point was by analysis of variance, 
corrected for multiple comparisons, p values below 0.05 were accepted as 
significant.
In Chapter 9, statistical significance between data samples for the in vitro work 
was tested by two-way ANOVA and statistical difference between pD2 values 
was by Student’s t-test. For the in vivo study, differences between placebo and 
active days was by Student’s t-test with subsequent Dunnett test.
In both cases, probability levels of p < 0.05 were considered significant.
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2.10 ETHICAL APPROVAL
All clinical study protocols had prior approval by the Glasgow West Ethical 
Committee, Informed written consent was also obtained from all participants, 
with the exception of the acute asthma study as it was thought that this would 
delay treatment of such patients and venepuncture was considered to be a normal 
part of the assessment process in the Accident and Emergency Department. 
Following admission however, patients were informed that venous blood samples 
requested on days 2 and 5 were for research purposes and were allowed to 
decline if they wished.
CHAPTER 3
THE RENIN-ANGIOTENSIN SYSTEM IN 
ACUTE SEVERE ASTHMA
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3.1 INTRODUCTION
This first study was stimulated by an earlier observation made by ourselves while 
examining hormonal responses in acute asthma. In this preliminary study we were 
surprised to discover marked activation of the renin-angiotensin system (RAS) in 
patients admitted to hospital with an acute exacerbation of asthma. However, as far as 
we are aware, the activity of the RAS in asthma had not been previously described, 
and the effect of the hormone ANG II on lung function in man was unknown. Ha\ ing 
consulted the relevant literature, it was discovered that ANG II had recently been 
shown to potentiate bronchoconstriction of rabbit airway smooth muscle in \ itro 
(126). We therefore decided to extend and confirm our earlier observation by 
measuring plasma levels of renin and ANG II in a larger group of patients with acute 
severe asthma admitted to our hospital. Furthermore, we were also interested to 
compare these results with those levels obtained in stable patients with mild chronic 
asthma taking only inhaled bronchodilator therapy on an as-required basis, a group of 
severe chronic asthmatics on regular home nebulisers and a healthy non-asthmatic 
control group.
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3.2 PATIENTS AND METHODS
Plasma renin and ANG II levels were therefore measured in 4 groups of subjects :
Group 1) 20 (6  male) patients admitted non-consecutiveiy (2 patients admitted 
twice) to Accident and Emergency with acute severe asthma. IMean (SD) age 34 
(12.9) years, PEER 125 (38) 1/min, Pa02 9.2 (3.3) kPa (on air), pulse rate 120 (15) 
beats/min on admission]. Venous blood was withdrawn shortly after admission for 
estimation of plasma renin, ANG II, catecholamines (adrenaline and noradrenaline) 
and haematocrit. Arterial blood gases (ABG's) were sampled on air from the radial 
artery and peak expiratory flow rate (PEER) was recorded. Patients were treated as 
deemed appropriate by the attending physician and all measurements (with the 
exception of ABG's) were repeated on day 2 and day 5 after admission.
All patients had received nebulised E2  agonists (salbutamol) and four were given 
intravenous hydrocortisone in the Accident and Emergency Department prior to 
venesection. Seventeen patients were taking regular inhaled corticosteroids, 5 oral 
theophylline and 10 were on oral prednisolone. All used as required inhaled B2  
agonists via metered dose inhaler (6  of these in addition were taking B2  agonists via 
home nebuliser), 4 inhaled salmeterol and 4 inhaled ipratropium bromide. No 
patients were receiving oral B agonists. Only one patient was on regular oral diuretic 
therapy (frusemide).
Group 2) 9 (2 male) patients with mild chronic asthma, mean (SD) age 40.3 (13) 
years, PEER 450 (59) 1/min, mean O 2  saturation 96.8 (1.2)%. All were taking as 
required inhaled B2  agonists via metered dose inhaler and 6  regular inhaled 
corticosteroids.
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Group 3) 10 (2 male) patients with severe chronic asthma taking regular nebulised 
B agonists (salbutamol), mean (SD) age 393 (15) years, PEFR 225 (48) 1/min, O2  
saturation 97 ( 1.8 )%. In addition, all were taking regular inhaled corticosteroids, 4 
nebulised ipratropium bromide, 3 oral theophylline and 3 maintenance doses of oral 
prednisolone.
Group 4); 16 (5 males) normal volunteers, mean age 36.6 (11.4) years, PEFR 507 
(77) 1/min, O2  saturation 98 (1.3) %.
Patients in groups 2 and 3 were requested to withhold their B2  agonists for 6  hours 
prior to venesection.
Measurements
Renin, ANG II, catecholamines - see Chapter 2.4, Hormone assays 
Haematocrit - see Chapter 2.5 
Arterial blood gases - see Chapter 2.6
Oxygen saturation - pulse oximeter and finger probe (Ohmeda Biox 3700E; 
Ohmeda, Louisville, USA).
PEFR - Wright mi ni-peak flow meter.
Statistical analysis
Differences in plasma renin and ANG II between the groups was evaluated using the 
Mann-Whitney U- test. The absolute number of patients with elevated renin and ANG 
II levels in each group was compared using the jr ^ test, 
p values below 0.05 were accepted as significant.
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3.3 RESULTS
In the acute severe asthma group, plasma renin was significantly elevated (p<0.05) on 
days 1, 2 and 5 when compared to the mild chronic asthmatics, the severe chronic 
asthmatics and our non asthmatic control group. Plasma ANG II was only 
significantly elevated on day 5 when compared with the other groups (figure 3.1 and 
table 3.1).
When the groups were compared for the absolute number of individuals with elevated 
ANG II levels there were also significant differences. In the acute asthma group, 15 
out of 2 0  patients had elevated ANG II levels compared to 3 of the 9 mild asthmatics 
and 5 of the 16 controls [x^ = 7.74 and 4.05 respectively, p< 0.05].
There was no significant difference in plasma renin and ANG II levels between the 
mild chronic asthma group, the severe chronic asthma group and the normal 
volunteers.
There was no correlation between plasma ANG II levels and systolic blood pressure 
on admission in the acute severe asthma group.
Raw data for this chapter is included in the Appendix [tables lA  to 7A].
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Acute severe Mild chronic Severe chronic Normal
asthma asthma asthma volunteers
Day 1 2 5
RENIN 48.7 * 44.2 * 45.5* 19 22 20
(qU/ml) (24-79) (15-75) (21-70) (12.5-25.5) (17-32) (12-24.3)
ANG II 32.5 38 56 * 12.5 12.2 11.3
(pg/ml) (7.5-75) (6-105) (12-109) (6-19.5) (7.7-18.8) (9-17)
Table 3.1 . Plasma renin and ANG II levels in acute severe asthma, mild chronic 
asthma, severe chronic asthma and normal volunteers (results expressed as 
median with interquartile range) *p<0.05 versus mild chronic asthma, severe 
chronic asthma and noraial volunteers.
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Fig 3.1 Scatter plot (log scale) illustrating individual plasma renin and angiotensin 
11 (ANG II) levels in acute severe asthma [n=20], mild chronic asthma [n=9], 
severe chronic asthma [n=10], and controls [n=16]. Bars represent median values. 
In acute severe asthma, plasma renin was significantly elevated (p<0.05) on days 
1 , 2 and 5, and ANG II significantly elevated (p<0.05) on day 5 only, when 
compared to the other groups.
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3.4 DISCUSSION
This is the first study to document activation of the RAS in acute severe asthma. 
In addition, we have shown that the levels of renin and ANG II in acute severe 
asthma are significantly elevated when compared to a non asthmatic control group 
and a group of mild chronic asthmatics or severe chronic asthmatics who had 
withheld their B agonist therapy. Plasma renin levels were noted to be 
significantly elevated on days 1, 2 and 5 after admission, and although ANG II 
was also elevated, this only reached statistical significance on day 5. However, it 
is possible that the lack of significance on the first two days may be the result of 
the small sample size. The reason for the wide range of variations in plasma renin 
and ANG II levels in the patients is not certain, but may related to differences 
between individuals in factors influencing the RAS.
The stimulus to this activation of the RAS in asthma, and the effects of ANG II on 
lung function in man are unclear. Since B adrenoceptors are known to be present 
on juxtaglomerular cells (74). it is possible that nebulised 8 % agonist therapy used 
in the treatment of acute asthma could be responsible for this activation. In 
support of this suggestion is our observation that plasma renin and ANG II levels 
remained elevated on days 2 and 5 when the patients were recovering from the 
acute attack of asthma (as demonstrated by increased peak flow rates) but still 
continued to receive nebulised bronchodilator therapy. In addition, increases in 
plasma renin activity in normal subjects has been described following intravenous 
infusion of salbutamol and also after the 8 2  agonists fenoterol and salbutamol 
administered by metered dose inhaler (129,82). Hypoxia may also cause 
activation of the RAS, although studies which have examined this effect in 
animals and in man have produced conflicting results (140,141). In stable cor
46
pulmonale the RAS has been reported not to be activated (141) while others have 
observed elevated levels of ANG II in patients with airflow obstruction and 
arterial hypoxaemia (128). Other stimuli which could cause activation of the RAS 
in acute severe asthma include circulating catecholamines. Ind et al have reported 
elevated plasma noradrenaline (NA) levels in patients admitted with acute severe 
asthma (eg; mean (SEM) plasma NA of 7,7 (0.6) nmol/1), although adrenaline 
levels were not increased in any cases (130). We have not found convincing 
evidence of this in our own study, where in the majority of patients plasma 
catecholamines were within the normal range (Table 4A, Appendix). Other 
possible stimuli are hypovolaemia and drugs such as diuretics. There was a small 
but significant increase in the mean haematocrit value on the day of admission 
when compared to day 2 and 5 in our acute asthma patients, although individual 
values remained within the normal laboratory reference ranges on all 3 days 
(Table 3A, Appendix). This elevation in haematocrit on admission probably 
reflects the haemoconcentration resulting from insensible loss of water in the 
breath as a result of prolonged hyperventilation during an acute attack of asthma. 
However, it is unlikely that such a minor degree of haemoconcentration would 
explain activation of the RAS lasting until day 5 after admission. Only one acute 
asthma patient was receiving regular oral diuretic therapy and it is also unlikely 
that inhaled or oral steroid therapy is responsible for this activation of the RAS in 
acute asthma. Although cortisol has been reported to increase renin substrate 
(angiotensinogen) levels (142), prednisolone given to normal volunteers in doses 
of 50mg/day has no effect on plasma renin activity (143) and there was no 
evidence of activation of the RAS in our 3 severe chronic asthmatics who were 
taking oral steroids at the time of venesection. The effect of oral theophyllines on 
the RAS is unknown. The role of inflammatory mediators such as histamine or
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prostaglandins on the activity of the RAS is also unclear, although it is of interest 
that proteinase enzymes secreted by mast cells have been shown to cause rapid 
conversion of ANG I to ANG II by an angiotensin converting enzyme (ACE) 
independent pathway (131).
Thus, in this initial study we conclude that the RAS is activated during acute 
severe asthma. Further studies should now be designed to explore possible stimuli 
to the release of ANG II during acute severe asthma and later to investigate 
whether the elevated ANG IT levels found in acute asthma might adversely 
influence lung function.
CHAPTER 4
THE EEFECT OF NEBULISED fi2 AGONISTS ON 
THE RENIN-ANGIOTENSIN SYSTEM IN MILD 
ASTHMATIC PATIENTS AND NORMAL VOLUNTEERS
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4.1 INTRODUCTION
The stimulus to the activation of the renin-angiotensin system (RAS) in acute asthma 
is unclear, but it is possible that high dose 8 % agonists used in the treatment of acute 
asthma could be responsible. In support of this is the observation that isoprenaline has 
been reported to stimulate the release of renin from isolated juxtaglomerular cells in 
vitro, this effect being mediated by 8  adrenoceptors (74). In addition, an increase in 
plasma renin activity has been reported following intravenous infusion of salbutamol 
in 4 healthy male subjects (129), and a dose dependent increase in plasma renin 
activity was noted after fenoterol and salbutamol administered by metered dose 
inhaler to normal subjects (82).
In the following study, we have investigated the effect of two commonly used 8 2  
agonists, salbutamol and fenoterol, on the activity of the RAS in both mild asthmatic 
patients and normal subjects.
49
4.2 METHODS 
Subjects
Eight stable mild asthmatic patients (2 male, 6  female), mean (SD) age 38(8.4) 
years, mean FEVi 82 (15) % predicted, and 8  non asthmatic volunteers, mean age 
34 (7.6) years were studied. All asthmatic patients were taking as required inhaled 
short acting 82 agonists, 7 of the 8  inhaled corticosteroids, and 2 an oral 
theophylline. Asthmatic patients were asked to withhold 8 2  agonists for at least 6  
hours, and oral theophyllines for 24 hours prior to each visit.
Study design
Subjects attended the laboratory on 3 non-consecutive study days. A 24 hour urine 
collection was obtained prior to each visit as an indirect means of assessing their 
dietary sodium intake. On arrival, an indwelling catheter (Venflon ®; Viggo AB, 
Helsingborg, Sweden) was inserted into a forearm vein for blood sampling. After 
a 20 minute rest, baseline spirometry (the best of 3 readings) was recorded and 30 
ml of venous blood was withdrawn for estimation of baseline plasma renin. ANG 
II and serum potassium.
Each subject then received either fenoterol (2.5mg in 3.5 ml normal saline), 
salbutamol (5mg in 3.5 ml normal saline) or placebo (3.5 ml normal saline) via a 
face mask and nebulizer driven by compressed air (CR 60 High Flou 
Compressor; Medic-Aid Ltd, Pagham, Sussex, UK.). Subsequent recordings of 
FEV1 (the best of 3 readings) were made at 15, 30, 60 and 120 minutes after 
nébulisation, and blood withdrawn at the same time points for estimation of
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plasma renin, ANG II and serum potassium. Subjects remained semi-recumbant 
for the duration of the test.
The study was approved by the Glasgow West Ethical Committee and informed 
consent was obtained from all participants. Subjects with known hypertension or 
taking regular diuretic therapy were excluded from participating.
All drugs were prepared in the sterile unit of our pharmacy and administered 
according to a randomised, double blind crossover study design.
Measurements
Spirometry (FEV 1) - see Chapter 2.2, Lung function.
Plasma renin and ANG II- see Chapter 2.4, Hormone assays.
24 hr urinary sodium - see chapter 2.7
Serum potassium - measured using standard ion selective electrodes.
Statistical analysis
Comparison of baseline values and the significance of changes in these at each 
time point was by analysis of variance, corrected for multiple comparisons, p 
values below 0.05 were accepted as significant.
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4.3 RESULTS
1. Plasma renin and ANG II
There were no significant differences between baseline values of plasma renin and 
ANG II on either study day or between asthmatic patients and normal subjects, 
although we note that one individual in the asthmatic (fenoterol) group had a high 
baseline ANG II level which tended to skew the mean baseline value for this 
particular group (table 4.1).
In the asthmatic patients, renin levels were significantly elevated after both 
salbutamol and fenoterol at 120 minutes, and ANG II at 15 minutes after fenoterol 
alone, when compared to placebo p< 0,05 (figure 4.1).
In the normal subjects, there was a trend for renin levels to increase after fenoterol 
and salbutamol although the results were not statistically significant when 
compared to placebo. ANG II levels however were significantly higher than 
placebo 30 and 60 minutes after inhalation of salbutamol p<0.05 (figure 4.2),
2. 24 hour urinary sodium
There were no significant differences between 24 hour urinary sodium 
concentrations on any of the study days. Mean (SEM) urinary sodium values were 
145.4 (25.1), 160 (23) and 172 (23.1)mmol/ 24 hr in the asthmatic patients, and 
170 (24.9), 172 (21.2) and 157 (25.8) mmol/ 24hr in the normal subjects, prior to 
fenoterol, salbutamol and placebo respectively
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3. Serum potassium
Mean (SEM) baseline potassium levels were similar between the groups on each 
study day. In the asthmatic patients baseline values were 4.4 (0.2), 4.3 (0.2). and 
4.5 (0.2) mmol/1, and in the normal subjects 4.8 (0.2), 4.4 (0.2) and 5.0 (0.2) 
mmol/1 prior to inhalation of fenoterol, salbutamol and placebo respective!). 
Fenoterol and salbutamol both caused significant decreases in serum potassium 
when compared to placebo, p<0.05 (figure 4.3). At 60 minutes, mean (SEM) 
absolute fall in potassium levels were 0.8 (0.2), 0.5 (0.3) and 0.1 (0.1 ) mmoi/l in 
the asthmatic patients and 0.8 (0.3), 0.5 (0.2) and 0.1 (0.1) mmol/1 in the normal 
subjects after inhalation of fenoterol, salbutamol and placebo respective!). In 
addition, the effect of fenoterol was significantly greater than salbutamol at 60 
minutes (p<0.05) in both the asthmatic patients and normal subjects. The lowest 
recorded potassium level in our study was 2.9 mmol/1 (after fenoterol).
4. FEVi
In the asthmatic patients, both salbutamol and fenoterol increased FEVi 
compared to placebo, the effect being maximal at 60 minutes. The degree of 
bronchodilatation was similar for each agent. Mean (SEM) baseline values of 
FEV 1 were 2.45 (0.45), 2.54 (0.31) and 2.25 (0.34) litres with a mean (SEM) 
absolute change in FEV j of 0.55 (0.04), 0.52 (0.05) and 0.04 (0.03) litres after 
inhalation of fenoterol, salbutamol and placebo respectively.
In the normal subjects there was no significant change in FEVi after either 
fenoterol or salbutamol (data not shown).
Raw data for this chapter is included in the Appendix [tables 8A to 13A].
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Fenoterol
Renin ANG II
Salbutamol
Renln ANG II
Placebo
Renln ANG II
Asthmatic 24.2 19.1
patients (4.4) (8.3)
31.5
(8 .4 ) 8.6( 1 . 1 )
30.4
(7.5)
8.1
(3.5)
Normal 32.8 11.0
subjects (6.1 ) (2.6)
29.2
(6 .3 ) 11.5(3.3) 26.5(6.7) 13.1(3.9)
Table 4.1 Mean (SEM) baseline values of plasma renin (pU/ml), and angiotensin 
II (ANG II) (pg/ml) in asthmatic patients [n=8 ] and normal subjects [n=8 ].
No significant differences.
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Figure 4.1 The effect of 8% agonists on plasma renin and angiotensin II (ANG II) 
levels in asthmatic patients [n=8 ].
Results as mean (SEM) absolute change from baseline values. =^p<0.05 vs placebo 
□  fenoterol (2.5mg), ■  salbutamol (5mg), #  placebo
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Figure 4.2 The effect of 132 agonists on plasma renin and angiotensin II (ANG 
II) levels in normal subjects [n=8 ].
Results as mean (SEM) absolute change from baseline values. *p<0.05 vs placebo 
□  fenoterol (2.5mg), ■  salbutamol (5mg), #  placebo
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Figure 4.3 The effect of B2  agonists on serum potassium levels in asthmatic 
patients and normal subjects [n= 8  in each case]. Results expressed as % change 
from baseline values. *p<0.05 vs placebo ** p< 0.05 vs salbutamol
□  fenoterol (2.5mg), ■  salbutamol (5mg), #  placebo
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4.4 DISCUSSION
This particular study was designed to examine whether high dose 8 2  agonists 
might be responsible for the high levels of plasma renin and ANG 11 noted in 
patients with acute exacerbations of asthma, and our results demonstrate that these 
agents can activate the RAS in both mild asthmatic patients and normal 
volunteers. We chose to study two commonly used 8 2  agonists, namely fenoterol 
and salbutamol, administered in high doses that are recommended in the British 
National Formulary for the treatment of acute severe asthma, or in patients 
receiving domiciliary nebulised bronchodilator therapy.
Renin release from the juxtaglomerular cells of the kidney is regulated by a 
number of factors. These include sympathetic nervous system activity, renal 
perfusion pressure and sodium and potassium balance (74). The 8 adrenoceptor 
subtype involved in the renin-releasing response has been the subject of much 
controversy, and although it is now generally accepted that renin release is 
mediated primarily by 8 ] receptors (144), 8 2  agonists have clearly elevated 
plasma renin in some studies. Although Davies et al reported no effect of 
intravenous salbutamol on plasma renin activity in healthy subjects (145) and 
Rahman et al noted that plasma renin activity was unaffected by inhaled 
terbutaline (146), Phillips et al observed an increase in plasma renin activity 
following intravenous infusion of salbutamol in 4 healthy male subjects (129), 
and Scheinin and co-workers found a dose dependent increase in plasma renin 
activity after both fenoterol and salbutamol administered by metered dose inhaler 
to 6  normal subjects (82). However none of these studies measured changes in 
plasma ANG II.
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The exact mechanisms whereby salbutamol and fenoterol may stimulate renin 
release in the present study are not entirely clear. It has been suggested that the 
increased renin secretion by 132 agonists may result from a weak agonist action of 
these drugs on renal 6 j adrenoceptors (71), while other postulated mechanisms 
include increased sympathetic activity due to activation of presynaptic facilitatory 
132 adrenoceptors, local vascular effects with resultant changes in renal perfusion 
pressure, or that renin release is stimulated by the hypokalaemic effect of (32 
agonists (129). It is also intriguing to speculate on the possible existance of a local 
tissue RAS in the airway, similar to that found in other tissues (106), and whether 
such a mechanism may contribute to elevations in plasma renin and ANG 11 
following the inhaled route of administration.
The hypokalaemic and bronchodilator effects of salbutamol and fenoterol are well 
documented, and our results are in close agreement with those of others (147- 
151). However, the results for renin and ANG II are more difficult to interpret. 
This is possibly due to our small sample size and also what appears to be a wide 
variability in each individual’s response to the effect of 132 agonists on the RAS. 
In the group of normal volunteers, there was an obvious trend for renin to increase 
after both salbutamol and fenoterol, although this did not quite reach statistical 
significance. However, plasma ANG 11 was elevated significantly after salbutamol 
but not fenoterol. In the asthmatic group renin was significantly elevated after 
both 132 agonists, yet it was fenoterol and not salbutamol which sigificantly 
increased ANG 11 in the plasma. For an unknown reason, one individual in the 
asthmatic (fenoterol) group had a high baseline plasma ANG 11 which tended to 
skew the mean value for this group (table 4.1). However the plasma renin for this 
individual was normal and we think that this higher baseline ANG II is unlikely to 
be of any importance with respect to the results. The reason for the differences in
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the ability of fenoterol and salbutamol to elevate ANG IT in each group is not 
clear. We might hypothesise that the greater degree of hypokalaemia induced by 
fenoterol may stimulate the RAS more so than salbutamol. However this theory 
does not hold when applied to the group of normal volunteers. Although we did 
not measure blood pressure in the present study, increases in systolic and 
decreases in diastolic blood pressure have been reported following inhaled 
salbutamol and fenoterol (147). It is possible that the apparent differences 
between these agents on the activity of the RAS could be the result of differing 
alterations in renal haemodynamics and hence renin release. It has also been 
suggested that perhaps the adrenoceptor involved in the release of renin does not 
fit the normal classification of B adrenoceptors (152). These theories do not 
however clearly explain the differing effects of fenoterol and salbutamol in the 
two groups of subjects.
Although the plasma levels of renin and ANG II recorded following single doses 
of nebulised B2  agonists are less than the range of levels we observed in acute 
severe asthma [e.g. renin 45.5 (21-70) pU/ml and ANG II 56 (12-109) pg/ml on 
day 5 after admission, results as median with interquartile range](Chapter 3), in 
the emergency treatment of acute asthma repeated doses of B agonists are often 
administered and are recommended in recent guidelines on the management of 
asthma should the patient fail to improve (60). Patients admitted to hospital with 
acute asthma show wide variations in circulating salbutamol and terbutaline 
concentrations, and in some individuals the B2  agonist levels are markedly 
elevated (153). Thus, circulating plasma levels of renin and ANG II may be 
further increased as a result of multiple dosing with B2  agonists. It therefore 
seems likely that B2  agonists are contributing to the activation of the RAS in acute 
severe asthma but it would be valuable in future studies to examine whether a
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dose dependent effect on renin and ANG II exists with repeated dosing, therefore
reinforcing our findings.
In conclusion, these results suggest that single high doses of nebulised 8 2  agonists 
commonly used in the treatment of asthma cause activation of the RAS both in 
mild asthmatic patients and normal volunteers. This appears to be an effect of 8 2  
agonists as a class, and further comment on our findings is not possible due to the 
presence of wide individual variations in response. It is possible that circulating 
ANG II levels might be further increased as a result of multiple dosing with 8 2  
agonists (as occurs in the treatment of acute severe asthma), and this hypothesis 
will be addressed in the next study.
CHAPTER 5
THE EFFECT OF INTRAVENOUS SALBUTAMOL 
AND MULTIPLE DOSES OF NEBULISED SALBUTAMOL 
ON THE RENIN-ANGIOTENSIN SYSTEM 
IN ASTHMA
61
5.1 INTRODUCTION
The results of the previous study demonstrated that single doses of nebulised 8 2  
agonists can elevate plasma renin and ANG II in mild asthmatic patients, 
suggesting that 8 2  agonists are likely to be contributing to the activation of the 
RAS in acute asthma. It was noted, however, that plasma levels of renin and ANG 
II following a single nebulised dose of salbutamol were significantly less than 
those measured in acute severe asthma. We therefore hypothesised that if repeated 
doses of nebulised 8  agonist were administered, as is often the case in acute 
asthma or in patients receiving domiciliary nebulised bronchodilator therapy, then 
this could perhaps have additive effects on circulating renin and ANG II levels. In 
addition, we have extended our earlier observation by investigating whether 
similar rises in circulating plasma renin and ANG II levels can occur following 
salbutamol administered by intravenous infusion, employing doses that are 
recommended for the treatment of acute severe asthma (60).
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5.2 METHODS 
Patients
Eight stable asthmatic patients (3 male), mean (SD) age 34 (7.5) years, mean 
FEV 1 82 (14.6) % predicted, were studied. All were taking as required short 
acting inhaled 8 2  agonists and 7 of the 8  regular inhaled corticosteroids. None 
were on oral 8 2  agonists, theophyllines or diuretic therapy. Patients were 
requested to withhold 82  agonists for at least 6  hours prior to each visit, but to 
continue with their inhaled corticosteroids unchanged. The study was approved by 
the Glasgow West Ethical Committee, and inforrned consent was obtained from 
all participants.
On arrival in the laboratory, an indwelling catheter (Venflon ®, Viggo AB, 
Helsingborg, Sweden) was inserted into a forearm vein for blood sampling, 
followed by a 30 minute rest. 30 ml of venous blood was withdrawn for 
estimation of baseline plasma renin, ANG II and serum potassium. A 24 hour 
sample of urine was collected by each patient prior to each study visit as an 
indirect means of assessing dietary sodium intake.
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Study 1: The effect of intravenous salbutamol on the renin-angiotensin 
system.
Subjects attended on 2 separate study days, at least a week apart. Each then 
received either salbutamol (5,10 and 20pg/min in increasing increments at 30 min 
intervals) or placebo (0.9% saline). The drugs were prepared in our pharmacy 
sterile unit and administered intravenously by means of a 50 ml syringe driver 
(Perfusor ®, Secura E, B Braun, Melsunger AG, Germany) according to a 
randomised double-blind crossover study design. At the end of each 30 minute 
infusion period, and 30 minutes after completion of the final infusion, blood was 
withdrawn for estimation of plasma renin, ANG 11 and serum potassium.
Study 2: The effect of multiple doses of nebulised salbutamol on the renin- 
angiotensin system.
On 3 separate study days each subject received (at time 0 and 30 mins) either 
salbutamol (5mg) followed 30 mins later by a further dose of salbutamol (5mg), 
salbutamol 5mg followed by placebo (3.5ml normal saline), or 2 placebo 
inhalations. The drugs were administered by nebuliser (CR 60 High flow 
compressor, Medic-Aid Ltd, Pagham, Sussex, UK) and face mask in a 
randomised, double-blind crossover manner. At baseline, and at 15, 30, 45, 60,90, 
120 and 150 mins, blood was withdrawn for estimation of plasma renin, ANG 11 
and serum potassium.
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Measurements
Plasma renin and ANG II - see Chapter 2.4 , Hormone assays.
24 hr urinary sodium - see chapter 2.7
Serum potassium was measured using standard ion-selective electrodes.
Statistical analysis
Comparison of baseline values and the significance of changes in these at each 
time point was by analysis of variance, corrected for multiple comparisons, p 
values below 0.05 were accepted as significant.
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5.3 RESULTS
Study 1 : The effect of intravenous salbutamol on the activity of the renin - 
angiotensin system in asthma. 
1. Plasma renin and ANG II
There were no significant differences between baseline values of renin or ANG 11 
on either study day [Mean (SEM) renin 21.7 (4.5)pU/ml and ANG II 6.7 (2.3 ; 
pg/ml prior to salbutamol, and renin 19.0 (6.4)pU/ml and ANG II 7.4 (2.3)pg/mi 
prior to placebo].
After the 10 and 20 pg/min infusions of salbutamol, plasma renin levels were 
significantly greater than placebo (p< 0.05). [Mean (SEM) absolute change in 
renin of 6.0 (3.5) and 5.1(4.1) pU/ml respectively after salbutamol and -0.43 (3.1 ) 
and -2.7 (2.7) pU/ml after placebo] (fig 5.1). ANG II levels were significantly 
greater than placebo (p<0.05) 30 mins after completion of the final infusion 
[Mean (SEM) absolute change in ANG II of 5.1 (4.3)pg/mi and -0.4 (0.69) pg/ml 
respectively] (fig 5.1).
2 . Serum potassium
There were no significant differences between baseline values of potassium on 
either study day. [Mean (SEM) potassium of 4.4 (0.1) mmoi/l and 
4.3(0.13)mmol/l prior to salbutamol and placebo respectively]. Serum potassium 
levels decreased after salbutamol and were significantly less than placebo after tlic 
10 and 20pg/min infusions and 30 mins after completion of the final infusion. 
[Mean (SEM) absolute change in serum potassium of -0.32 (0.1), -0.62 (0 .2 ) and 
-0.58 (0.28)mmol/l respectively, p<0.05 vs placebo] (fig 5.1).
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3. 24 hr urinary sodium.
There were no significant differences between 24 hr urinary sodium values on 
each study visit. Mean (SEM) urinary sodium values were 234 (43) mmol/ 24 hr 
and 185 (17.2) mmol/ 24hr prior to salbutamol and placebo respectively.
Study 2: The effect of multiple doses of nebulised salbutamol on the activity 
of the renin-angiotensin system in asthma.
1. Plasma renin and ANG II.
There were no significant differences between baseline values of renin and ANG 
11 on either study day. (renin 15.3 (3.2), 15.6 (2.6) and 14.7 (4.5) pU/ml and 
ANG 11 8 .6  (2.5), 6.1 (0.7) and 6 .8  (1.3) pg/ml prior to prior to inhalation of 
placebo, single and double doses of salbutamol respectively).
Plasma renin levels increased after both the single[SJ and double[D] doses of 
salbutamol and were significantly greater than placebo at 30 mins after S, and 45 
and 120 mins after D. (fig 5.2) [Mean (SEM) absolute change in plasma renin 
from baseline of 10.6 (3.9)pU/ml after S, and 17.4 (3.2) and 14 (3.2) pU/ml after 
D respectively p<0.05 vs placebo]. However there was no significant difference 
between the levels of plasma renin obtained after the single or double dose of 
salbutamol.
Plasma ANG II also increased after S and D and was significantly greater than 
placebo at 30 and 45 mins after S, and at 30 mins and all time points thereafter 
following D. ]Mean(SEM) absolute change in ANG 11 from baseline values of 
3.0 (2.6), and 2 .6  (2.5)pg/ml after S, and 3.7 (1.5), 9.9(5), 4.7(2.9), 7.0(2.1),
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5.1(2.0) and 4.3 ( l ,6 )pg/ml after D respectively, p<0.05 vs placebo]. In addition, 
the effect of D was significantly greater than S at 45 mins, p<0.05. (fig 5.2).
2. Serum potassium.
There were no significant differences between baseline values of potassium on 
either study day. [Mean (SEM) potassium of 4.4 (0.2), 4.3 (0.1) and 4.4 (0.1) 
mmol/1 prior to placebo, single and double doses of salbutamol respectively). 
Potassium levels decreased after the single and double doses of salbutamol and 
were significantly less than placebo, p<0.05, at 30 mins and all time points 
thereafter, following both S and D. [Mean (SEM) maximum fall in serum 
potassium of 0.85 (0.1 )mmol/l after S at 45 mins, and 1.16 (0.1 )mmol/l after D at 
150 mins]. In addition the effect of D on serum potassium was also significantly 
greater than S at 150 mins (fig 5.2).
3. 24 hr urinary sodium.
There were no significant differences between 24 hr urinary sodium values on 
each study visit. Mean (SEM) urinary sodium values were 140.4 (25.1), 160.9 
(24,9) and 112 (45.8) mmol/ 24hr in the normal subjects, prior to S, D and 
placebo respectively.
Raw data for this chapter is included in the Appendix [tables 14A-15A].
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Fig 5.1 The effect of intravenous salbutamol ( #  ) [after the first (5|.ig/min), 
second (lOjuig/min) and third (20 ixg/min)infusions], and placebo [5% dextrose] 
(O ) on plasma renin, ANG II and serum potassium (K+) in mild asthmatic 
patients. [n=8 ]
Results as mean (SEM) absolute change from baseline values. * p<0.05 vs 
placebo
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Fig 5.2 The effect of single ( □  ) and double ( A ) doses of nebulised salbutamol 
[5mgl, and placebo ( O  ) on plasma renin, ANG II and serum potassium (K+) in 
mild asthmatic subjects [n=:8 ]
Results as mean (SEM) absolute change from baseline values.
* p<0.05 vs placebo *p<0.05 vs single dose of salbutamol.
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SA DISCUSSION
The B2  agonist salbutamol administered either by intravenous infusion or by 
aerosol causes activation of the RAS in asthma. Administration of a second dose 
of nebulised salbutamol has further additive effects on plasma ANG ÎI levels. This 
finding therefore confirms and extends our earlier observations in asthmatic 
subjects that a single nebulised dose of the 132 agonist fenoterol can activate the 
RAS (Chapter 4). Although there was also a trend for plasma renin to increase 
after the second dose of 13 agonist in this study, the results did not reach statistical 
significance. This may, however, be partly explained by the small sample size and 
an apparent wide variation in individual responses to the effect of 132 agonists on 
the RAS. In addition, there is activation of the RAS by intravenous salbutamol 
when administered in doses recommended for the management of acute severe 
asthma (60), These results are in agreement with those of Phillips et al who 
described increases in plasma renin activity and decreases in serum potassium 
following intravenous infusions of the 132 agonists salbutamol (0.1, 0.4 and 0,7 
pg/kg/min) and rimiterol (0.5,1.0 and 2.0 nmol/kg/min) in 4 healthy male subjects 
( 329).
It is unclear why the rises in plasma renin and ANG II following intravenous 
salbutamol are smaller than those observed in the nebulised study. This may 
simply be a reflection of lower plasma drug concentrations following the 
intravenous route of administration. Presumably renin release follows systemic 
absorption of the drug to stimulate B adrenoceptors on the juxtaglomerular cells of 
the kidney directly, or alternatively, it is interesting to speculate that the more 
marked elevations in renin and ANG II following the inhaled route may be due to
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an additional activation of a local RAS in the airway, similar to those found in 
other tissues (106).
We previously hypothesised that B agonist treatment may contribute to the high 
levels of plasma renin and ANG II noted in patients with severe asthma (Chapter 
3). However, even following repeated dosing with nebulised 02 agonists it is 
apparent that the plasma levels of renin and ANG II attained are still less than 
those measured in acute severe asthma [eg results as median with interquartile 
range; renin 45.5(21-70)pU/ml and ANG II 56(12-109)pg/ml on day 5 after 
admission]. This raises the possibility that there must be other additional stimuli 
to the activation of the RAS in acute asthma such as hypoxia or inflammatory 
mediators, thus leading to marked elevations in circulating plasma renin and ANG
II.
CHAPTER 6
AN INVESTIGATION OF THE MECHANISM OF
B2-a g o n i s t -i n d u c e d  a c t iv a t io n  o f
THE RENIN ANGIOTENSIN SYSTEM
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6.1 INTRODUCTION
In the renin-angiotensin system (RAS), the octapeptide hormone ANG II is 
generated in a biological cascade in which the enzyme renin cleaves ANG I from 
the large molecular weight precursor angiotensinogen. ANG I is subsequently 
activated to ANG II by angiotensin converting enzyme (ACE), mainly in the 
pulmonary circulation, but also in other vascular beds and other tissues including 
the myocardium and coronary arteries. In addition, there is currently interest in the 
existance of alternative pathways for ANG II synthesis, for example Reilly et al 
have reported that ANG 1 can be rapidly converted to ANG II by human 
neutrophil cathepsin G and also by skin mast cell chymase enzymes (6 6 ).
We have reported that high dose nebulised 132 agonists used in the treatment of 
asthma can elevate plasma renin and ANG II in mild asthmatic patients and 
healthy volunteers, suggesting that 132 agonists are likely to contribute to the 
activation of the RAS in acute asthma. In this study we sought to determine the 
mechanism responsible for this activation. We examined the influence of ACE 
inhibition with the drug lisinopril in a group of healthy subjects, thereby testing 
our hypothesis that high dose 132 agonists cause elevation in plasma ANG II via 
the classical components of the RAS including ACE.
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6.2 METHODS 
Subjects
Eight healthy volunters (3 male), mean (SD) age 28 (4.6) years were recruited to 
the study. All were non-smokers, with no history of hypertension or heart disease. 
None was taking any regular medication. Informed, written consent was obtained 
from each subject and the study was approved by the Glagow West Ethical 
Commitee.
Study design
Subjects attended the laboratory on 4 separate study days at least a week apart, 
and all at approximately the same time of day (12.00-14.00 hrs). Three hours prior 
to attending, subjects took either lisinopril (2 0 mg) or an identical placebo capsule. 
On arrival, an intravenous cannula (Venflon®, Viggo AB, Helsingborg, Sweden) 
was inserted into a forearm vein following which subjects rested for 30 mins in 
the supine position. Baseline blood pressure (mean of 3 readings) was measured 
and blood was withdrawn for estimation of plasma renin and ANG II, serum ACE 
and potassium. Each subject then received either salbutamol or placebo 
inhalation. Thereafter subjects remained supine for the duration of the visit, and 
blood was withdrawn at 15, 30, 60, 90 and 120 minutes for measurement of 
plasma renin, ANG II and serum potasium. Serum ACE was measured 120 mins 
after nébulisation. Blood pressure was monitored at 15 minute intervals 
throughout the study.
Salbutamol (5mg) or placebo inhalation (3.5ml normal saline) were given by 
nebuliser (CR60 High Flow Compressor, Medic-Aid Ltd, Pagham, Sussex, UK) 
and face mask. All drugs were prepared in the sterile unit of the pharmacy, and
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administered according to a randomised, double-blind, crossover study design, so 
that after all four vists each subject had received all possible combinatons of 
capsules and nebuliser solution.
Measurements
Plasma renin, ANG II and serum ACE - see Chapter 2.4 , Hormone Assays. 
Serum potassium - measured using standard ion-selective electrodes.
Blood pressure recorded by semi-automatic sphygmomanometer (Dinamap®, 
1846 EX vital signs monitor, Critikon, Berkshire, UK) and the mean of 3 readings 
at each time point recorded.
Statistical analysis
Comparison of baseline values and the significance of changes in these at each 
time point was by one way analysis of variance corrected for multiple 
comparisons,
p values below 0.05 were accepted as significant.
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6.3 RESULTS
1. Plasma renin and ANG II
Baseline plasma renin levels were significantly higher after lisinopril but there 
were no significant differences between baseline renin levels on the non-lisinopril 
days nor between the lisinopril days (table 6.1  )
Following salbutamol alone, plasma renin levels increased, being significant!\ 
higher than placebo at 15, 30 and 45 mins [Mean (SHM) absolute change in 
plasma renin of 26.1(7.9), 16.6(3.9) and 14.1(4.9) pU/ml respectively, p<0.05 
vs placebo].
When lisinopril was administered prior to salbutamol, although initial baseline 
levels of renin were high, there were also further significant rises in plasma renin, 
[mean (SEM) absolute increase of 38.2 (15.6) and 26.7(9.3) pU/ml at 15 and 30 
mins, p< 0.05 vs placebo inhalation] (fig 6.1 ).
Baseline ANG IT levels were similar on the non-lisinopril days, and were 
significantly lower after lisinopril (table 6.1). Following salbutamol alone, plasma 
ANG Ï1 increased, being significantly higher than placebo at 15, 30, 45 and 90 
mins after nébulisation (Mean (SEM) absolute change in ANG 11 of 9.5 (3.4). 
5.7(1.9), 4.5(2.6) and 2.5(1.7) pg/ml, p< 0.05 vs placebo). However, when 
salbutamol was preceded by lisinopril, this rise in plasma ANG II was completel) 
inhibited (fig 6 .1).
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2. Serum ACE
Mean (SEM) serum ACE levels were 38.7(5.6) and 31.5 (9.6)U/L on the non- 
ACE inhibitor days prior to placebo and salbutamol inhalations respectively, and 
35.7 (6.5) and 32.5 (8.4) U/L at the end of the study.
Following lisinopril, serum ACE was <5 U/L at baseline in all except two 
subjects, in whom ACE levels were 5 and 8  U/L, Since our laboratory level of 
detection of ACE was 5U/L with a coefficient of variation of 30%, these values 
would lie within 2  standard deviations of this level and we can therefore assume 
that in all cases ACE activity was effectively suppressed. In addition, ACE levels 
remained suppressed at the end of the study.
3. Serum potassium
Baseline serum potassium levels were higher, although not significantly so, after 
lisinopril when compared to the non-lisinopril days (table 6.1 ). Salbutamol caused 
significant hypokalaemia, maximal at 45 mins after salbutamol alone (Mean 
(SEM) potassium of 3.08 (0.2) mmoI/1), and at 30 mins when preceded by 
lisinopril (3.4(0. l)mmol/l). The hypokalaemic response to salbutamol alone was 
greater than when salbutamol was preceded by lisinopril (Mean(SEM) decrease in 
serum potassium of 1 .2  (0 .2 ) mmol/ compared to 0 .8  (0 .2 ) mmol/1] (fig 6 .1).
4. Blood pressure and side effects
Mean blood pressure was not influenced by any of the treatments. One subject 
suffered dizziness and headache after lisinopril on each exposure. These 
symptoms were associated with marked falls in systolic blood pressure.
Raw data for this chapter is included m the Appendix [tables 16A-19A].
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renin ANG II ACE K+
Plac / Plac 27.5(5.1) 9.5(2.2) 38.7(5.1) 4.24(0.1)
Plac / Sal 35.6(8.3) 8 .2 (2 .2 ) 31.5(9.1) 4.26(0.16)
Lis / Plac 150.6(30.4)* 1.3(0.4)* <5* 4.31(0.07)
Lis / Sal 160.1(20.6)* 1.4(0. D* <5* 4.36(0.12)
Table 6.1
Mean (SEM) baseline values [ie; prior to administration of nebulised drug] of 
plasma renin (pU/ml), angiotensin II (ANG II) (pg/ml), serum ACE(U/L), and 
potassium(K+)(mmol/l) for the following treatment combinations ; 
pIac/plac=pIacebo capsules and placebo inhalation, plac/sal=placebo capsules and 
salbutamol, lis/plac = lisinopril and placebo inhalation, lis/sal= lisinopril and 
salbutamol. *p<0.05 vs plac/plac and plac/sal
Renin (uU/ml)
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150
1 0 0 -
50  -
0 -
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Fig 6.1 The effect of lisinopril pretreatment on salbutamol induced changes in 
plasma renin, ANG II and serum potassium (K"^) in healthy volunteers [n=8 ]. 
Results expressed as mean (SEM).
□  placebo I placebo inhalation 9  placebo/salbutamol [5mg]
#  lisinopril [2 0 mg] /placebo inhalation O  lisinopril / salbutamol [5mg]
* p<0.05 vs plac/plac ** p<0.05 vs lis /plac + p<0.05 vs lis / sal
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6.4 DISCUSSION
These results confirm our earlier findings that 8 2  agonists cause activation of the 
RAS. Pretreatment with lisinopril resulted in elevated plasma renin concentrations 
and reciprocal low plasma ANG II concentrations as a result of inhibition of ACE 
and consequent withdrawal of the inhibitory effect of ANG II on renin release 
(154). Although peak plasma concentrations of lisinopril occur approximately 6  
hours after administration ( 155), it was evident that serum ACE activity was 
effectively inhibited 3 hours following a single 20 mg oral dose in all our subjects 
and complete inhibition persisted throughout this observation period.
During ACE inhibition, the increase in plasma renin concentrations induced by 
nebulised salbutamol persisted but the rise in plasma ANG II concentration was 
completely suppressed. These findings strongly support the hypothesis that 
activation of the RAS by nebulised 8 2  agonists involves the classical components 
of the RAS, with conversion of ANG I to ANG II being mediated by ACE. The 
exact mechanisms whereby 8 2  agonists actually initiate renin release are not 
entirely clear. Alternative pathways for the conversion of ANG I to ANG II might 
also be involved. ANG I is rapidly converted to ANG II by neutrophil and mast 
cell proteinase enzymes (6 6 ); neither enzyme is inhibited by the ACE inhibitor 
captopril. The findings from this study suggest that elevation of plasma ANG II 
by 8 2  agonists is mediated by ACE. In inflammatory processes such as acute 
severe asthma, where very high levels of plasma ANG II were observed however 
(Chapter 3), it is conceivable that such alternative pathways of ANG II generation 
may contribute to the development of these higher levels of plasma ANG II.
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Our results also confirm previous observations concerning the hypokalaemic 
effect of 8 2  agonists (148,156). ACE inhibition tended to increase serum 
potassium and although potassium decreased in response to salbutamol even in 
the presence of lisinopril, this fall in serum potassium was less than that when 
salbutamol was administered alone. These findings differ from those of Rahman 
et al (146), who showed that although enalapril for one week protected against the 
hypokalaemic effect of inhaled terbutaline in healthy volunteers, there was no 
alteration in in the magnitude of fall in potassium following terbutaline. One 
explanation for these disparate findings may be more complete and prolonged 
inhibition of ACE with lisinopril.
In conclusion, the results of this study suggest that the effect of 8 2  agonists is 
mediated primarily by ACE and not by alternative pathways of ANG II 
generation. However, it seems unlikely that 8 2  agonists are solely responsible for 
the the very high levels of plasma ANG II observed in acute severe asthma, 
raising the possibility that perhaps hypoxia or inflammatory mediators such as 
mast cell proteinase enzymes may be contributing to this activation.
CHAPTER 7
THE EFFECT OF HYPOXIA AND B2-AGONISTS 
ON THE ACTIVITY OF THE RENIN ANGIOTENSIN 
SYSTEM IN NORMAL VOLUNTEERS
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7.1 INTRODUCTION
Activation of the RAS in asthma is likely to be due partly to 132 agonist therapy 
but the role of other putative stimuli such as hypoxia or inflammatory mediators is 
unclear. Patients admitted to hospital with acute exacerbations of asthma are 
invariably and often profoundly hypoxaemic (57,58) and Rees et al (157) have 
observed that hypoxia often persists for many days and sometimes weeks despite 
intensive therapy and apparent symptomatic relief. Moreover, airways obstruction 
as measured by FEV l (and therefore also PEER) was not found to be a reliable 
guide to the degree of hypoxaemia (157). Thus, it would seem reasonable to 
hypothesise that hypoxia may be stimulating the RAS in our acute asthmatic 
patients.
Previous studies which have examined the effect of hypoxia on the activity of the 
RAS in man have produced conflicting results (128,141), and therefore we were 
interested to investigate the effect of hypoxia on circulating renin, ANG 11 and 
ACE levels in a group of healthy volunteers. We chose to study normal subjects in 
the first instance, rather than asthmatic patients and, in addition, this study was 
extended to examine whether the effect of 132 agonists on the activity of the RAS 
might be influenced by the presence of hypoxic conditions.
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7.2 METHODS 
Subjects
Eight healthy non-smoking volunteers (4 male) between ages 22 and 40 (mean 
(SD) age 29.7(4.3) years) were recruited. None of the volunteers were taking any 
regular medication and none had any relevant past medical history. The study was 
approved by the Glasgow West Ethical Com mi tee and informed written consent 
was obtained from each subject prior to beginning the study.
Study design
Subjects attended the laboratory on 4 separate occasions at least a week apart. On 
arrival an indwelling cannula (Venflon ®, Viggo AB, Helsingborg, Sweden) was 
inserted into a forearm vein for blood sampling, followed by a 30 minute rest.
30 ml of venous blood was withdrawn for estimation of baseline plasma renin, 
ANG II and serum ACE. In addition, we also measured plasma catecholamines 
(noradrenaline and adrenaline). Pulse rate and oxygen saturation were recorded at 
baseline with the subject breathing room air and thereafter continously throughout 
the study by means of a pulse oximeter and finger probe (Ohmeda Biox 3700E; 
Ohmeda, Louisville, USA). Using a double-blind, placebo controlled crossover 
study design, each subject was randomised to breathe (via a mouthpiece 
connected to a non-rebreathing valve while wearing a nosed ip to occlude nasal 
airflow) either a normoxic or hypoxic (Ft 02 =12%) gas mixture for a period of 
30 minutes. The source of inspired gas was a reservoir bag connected to a 
constant flow of a mixture of oxygen and nitrogen. Oxygen and nitrogen were 
obtained from K and G sized cylinders respectively (BOC, Medishield, Harlow, 
Essex, UK), the oxygen and nitrogen being mixed in an oxygen blender prior to
83
entering the reservoir. The fractional inspired oxygen content of the mixture was 
determined by means of an oxygen analyser (5120 oxygen monitor, Ohmeda, 
Louisville, USA) and was controlled by changing the relative mixture of air and 
nitrogen to produce an inspired gas composed of either 12% or 24% oxygen. 
After the first 10 minutes, either salbutamol (5mg) or placebo (3.5 ml 0.9% 
saline) was introduced into the circuit via a nebuliser [CR 60 High Flow 
Compressor, Medic-Aid Ltd, Pagham, Sussex, UK] and nébulisation continued 
for 10 minutes or dryness, whichever occurred first. The nebuliser was then 
disconnected from the circuit and the gas mixture continued for the remaining 10 
minutes.
Blood samples for hormone estimation as above were withdrawn at 10, 20, 30, 
45, 60, 90 and 120 mins. Subjects remained semi-recumbant for the duration of 
the study.
Measurements
Plasma renin, ANG II, catecholamines and serum ACE - see chapter 2.4, 
Hormone assays.
Statistical analysis
Comparison of baseline values and the significance of changes in these at each 
time point was by one way analysis of variance corrected for multiple 
comparisons.
p values below 0.05 were accepted as significant.
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7.3 RESULTS
1. Oxygen saturation.
During the first 30 minutes peripheral oxygen saturations [mean (SEM)J were 96 
(1.6), 82 (1.5), 85 (3.9) and 84 (3.0)% on the combined hypoxia/salbutamol day 
and 97 (0.7), 83 (2.0), 84 (2.3), and 85 (1.9)% on the hypoxia/placebo day, at 0, 
10, 20 and 30 minutes respectively, returning to normal values within seconds of 
discontinuing the hypoxic mixture. There were no significant differences between 
oxygen saturations on the two hypoxia days.
2. Plasma renin and ANG II
There was no significant difference between baseline values of plasma renin and 
ANG n  on either study day (table 7.1). Following the period of hypoxia alone, 
there were no significant changes in plasma renin and ANG ÏÏ (fig 7.1). When 
salbutamol was included in the hypoxic mixture, there were significant increases 
in plasma renin and ANG TÏ levels, [mean (SEM) increase in ANG II of 
7.2(4,9),4.5(3.4), 5.4(2.9) and 3.6(3.1 ) pg/ml at 30, 45, 60 and 90 mins, and renin 
of 12.8(4.8), 15.5(6.3), 4.0(3.2) and 4.0(3.9) pU/ml at 45, 60, 90 and 120 mins 
respectively, compared to 1.1 (0.8), 1.1 (1.3), -0.5(0.9), 1.5 (2.7) and -4.4(2.6), 
-2.1(2.6),-4.0(3.3) and -6.0(2.7)fiU/ml after normoxia and placebo inhalation at 
the same time points, p< 0.05] (fig 7.1).
However, although nebulised salbutamol in the normoxic mixture also led to 
significant rises in plasma renin and ANG II when compared to nebulised placebo 
in normoxic mixture, [mean(SEM)increase in renin of 17.4 (6.4), 12.7(3.1), 
12.9(3.8), 9.7(3.8) and 11.4(3.5) pU/ml at 30,45, 60, 90 and 120 mins, and ANG 
II of 5.5(2.4), 8.6(4.1) and 8.3(4. l)pg/ml at 30, 45 and 60 mins respectively.
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p<0.05J, there was no significant difference between the effect of salbutamol on 
plasma renin and ANG II levels when administered in either the normoxic or 
hypoxic mixture (fig 7.1).
3. Serum ACE
Baseline serum ACE levels were similar (table 7.1) and did not change 
significantly at any time point on each study day (data not shown).
4. Plasma adrenaline and noradrenaline.
There was no significant difference between baseline noradrenaline (NA) and 
adrenaline (Adr) levels on either study day (table 7.1). Small but significant 
increases in plasma NA were noted after hypoxia, salbutamol, and hypoxia 
combined with salbutamol, this effect being significantly greater than normoxia 
and placebo inhalation at 20, 30 and 45 mins, p<0.05 [Mean (SEM) absolute 
increase of 1.69(0.5), 1.78(0.6), l.66(0.5)nmol/l after salbutamol alone, 0.7(0.2), 
0.85(0.3) and 1.34(0.3)nmol/l after hypoxia alone and 0.6(0.3), 0.8(0.4) and 
0.7(0.3)nmol/l after hypoxia combined with salbutamol] (fig 7.2). There was a 
transient peak in plasma Adr levels at 30 mins after hypoxia and salbutamol 
[mean(SEM) absolute increase of 0.83(0.6) nmol/1, p< 0.05 vs normoxia and 
placebo] (fig 7.2).
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5. Heart rate
Significant increases in heart rate occurred in response to hypoxia, salbutamol and 
also hypoxia combined with salbutamol eg; mean (SEM) maximum increase in 
heart rate from baseline values (table 7.1) of 12 (1.4), 18 (2.5) and 32 (3.1) 
beats/min at 30 mins after hypoxia/placebo, normoxia/salbutamol and hypoxia / 
salbutamol respectively (fig 7.3).
Raw data for this chapter is included in the Appendix [tables 20A - 25A].
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renin ANG II NA Adr ACE HR
norm/plac 23.0(5.0) 7.4(2.6) 2 .6(0.2) 0.15(0.02) 40.7(5.0) 85(4)
norm/sal 23.3(4.8) 6.6(1.2) 2.6(0.2) 0.15(0.02) 31.5(6.4) 82(3)
hyp/plac 30.7(6.9) 9.2(2.7) 2.6(0.4) 0.14(0.03) 39.3(5.9) 83(5)
hyp/sal 29.0(7.0) 7.5(1.6) 2.5(0.3) 0.14(0.02) 33.1(8.8 82(5)
Table 7. 1
Baseline values of plasma renin (pU/ml), angiotensin II (ANG II) (pg/ml), 
ACE(U/L), noradrenaline (NA)(nmol/l), adrenaline (Adr)(nmol/l) and heart 
rate(HR) (beats/min). Results expressed as mean (SEM) [n=8].
No significant differences.
norm/plac = normoxia and placebo inhalation, norm/sal = normoxia and 
salbutamol 5mg, hyp/plac = hypoxia and placebo inhalation, hyp/sal= hypoxia 
and salbutamol 5mg.
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Fig 7.1 The effect of hypoxia and nebulised salbutamol [5mg] on plasma renin 
and angiotensin II (ANG II) levels in normal subjects. [n=8 ]
Results as mean absolute change from baseline values.
* p<0.05 vs normoxia /placebo
□  = hypoxia and placebo inhalation, O  -  hypoxia and salbutamol 5mg,
■  -  normoxia and placebo inhalation, #  = normoxia and salbutamol 5mg
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Fig 7.2 The effect of hypoxia and nebulised salbutamol [5mg] on plasma 
noradrenaline and adrenaline levels in normal subjects. [n=8 ]
Results as mean absolute change from baseline values.
* p<0.05 vs normoxia /placebo 
□  = hypoxia and placebo inhalation, O  = hypoxia and salbutamol 5mg,
■  = normoxia and placebo inhalation, #  = normoxia and salbutamol 5mg
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Fig 7.3 The effect of hypoxia and nebulised salbutamol [5mg] on heart rate in 
normal subjects. [n=8 ]
Results as mean absolute change from baseline values.
* p<0.05 vs normoxia /placebo
□  = hypoxia and placebo inhalation, O  = hypoxia and salbutamol 5mg,
9  = normoxia and placebo inhalation, •  ~ normoxia and salbutamol 5mg
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7.4 DISCUSSION
This study was designed to examine whether hypoxia might be contributing to the 
activation of the RAS in acute severe asthma and, in addition, to investigate 
whether the stimulatory effect of 132 agonists on the RAS is influenced by the 
presence of hypoxic conditions. Our subjects received a 30 minute period of 
hypoxia where the FiO^ was maintained at 12%, resulting in a mean 0 % saturation 
of 83.4%. During and after this period of hypoxia alone there was no change in 
the activity of the RAS in the group of eight healthy volunteers. Our findings also 
confirm our earlier observation that there is activation of the RAS by high dose 
nebulised 6 2  agonists (Chapters 4 and 5) but that this effect is not enhanced b\ the 
presence of hypoxia.
Previous studies which have examined the effect of hypoxia on the activity of the 
RAS in animals and man have produced a variety of results: Rats exposed to 
chronic hypoxia develop a rise in renin and renin substrate (127), and hypoxaemia 
has been reported to cause moderate activation of the RAS in conscious dogs
(158). In stable cor pulmonale the RAS has been reported not to be activated 
(141), while others have observed elevated levels of ANG II in patients with 
airflow obstruction and arterial hypoxaemia (128). Although the availability ol 
serum ACE has been shown to be reduced by alveolar hypoxia in dogs ( 140). the 
effect of hypoxia on ACE activity in man is less clear. Some authors claim that 
the activity of ACE is reduced by hypoxia eg in normal subjects at high altitude
(159), whereas our findings are in agreement with those of Colice and Ramirez, 
who found no change in ACE activity or plasma renin after a 60 minute period of
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hypoxaemia in 5 normal subjects during which the oxygen saturation was 
maintained at 80% (160), and Lawrence et al who reported no change in plasma 
renin activity or ANG II in a group of 7 male subjects after a similar 60 minute 
period of hypoxia with an F i0 2  of 12% (161). Thus, there may be species 
differences and in addition the degree and duration of hypoxia may be important. 
The increase in heart rate in our subjects, coupled with the small rise in plasma 
NA levels in response to the stress of hypoxia, suggests sympathetic nervous 
system activation. In previous studies, mild hypoxia (F i02  15%) has been 
reported to be without effect on circulating plasma catecholamines or heart rate 
(162) although higher levels of hypoxia (Fi02 7-10%) have increased sympathetic 
output and caused a tachycardia (163). A rise in plasma noradrenaline by 
salbutamol has been described previously (82,164), and is thought to result from 
a direct stimulatory effect of salbutamol on prejunctional 8 2  adrenoceptors, 
thereby facilitating neurotransmitter release from sympathetic nerve endings.
In conclusion, there is no evidence from the present study in healthy volunteers to 
support our hypothesis that hypoxia stimulates the RAS. Although there are 
characteristic pathophysiological differences between the airways of asthmatic 
subjects and healthy volunteers, hypoxia in a range similar to that obtained in our 
experiments typically occurs during acute exacerbations of asthma, thus it would 
seem very unlikely that hypoxia is activating the RAS in acute severe asthma. 
However, we cannot exclude the possibility that the asthmatic subject may 
respond differently or perhaps that more severe or prolonged degrees of hypoxia 
could cause activation of the RAS in asthma
We have also confirmed our earlier findings that high dose 6 2  agonists used in the 
treatment of asthma can cause elevations in circulating levels of plasma renin and
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ANG II, but this effect is not enhanced by the presence of hypoxia. The levels of 
renin and ANG II after salbutamol are less than those observed in patients with 
acute severe asthma (eg, plasma renin of 45.5[21-70] pU/ml and ANG II of 
56112-109] pg/ml on day 5 after admission, results as median with interquartile 
range) and it is possible that other factors may contribute to the activation of the 
RAS in acute asthma, perhaps inflammatory mediators such as histamine, 
prostaglandins or proteinase enzymes released from mast cells (130). The precise 
role of these other stimuli remains to be established in a future study.
CHAPTER 8
THE EFFECT OF INFUSED ANGIOTENSIN II ON 
AIRWAY FUNCTION IN ASTHMA
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8.1 INTRODUCTION
Although ANG II is known to be a potent constrictor of vascular smooth muscle 
(102), its effects on bronchial smooth muscle remain unknown. Recent work has 
suggested that ANG II can potentiate contraction of rabbit airway smooth muscle 
in vitro (126) raising the possibility that this hormone may possess 
bronchoconstrictor activity in vivo. Having previously demonstrated elevated 
plasma levels of ANG II in patients with acute severe asthma and also after high 
dose B2  agonist therapy, we have now examined the effect of ANG II on airway 
function in a group of mild asthmatic patients.
We chose to administer ANG 11 as an intravenous infusion, employing doses 
recommended by our colleagues in the MRC Blood Pressue Unit, Western 
Infirmary. Such dose ranges should be expected to increase plasma concentrations 
of ANG II to similar levels that occur in acute severe asthma (see Chapter 3) with 
only minimal increases in blood pressure.
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8.2 METHODS 
Patients
Eight (4 male) mild asthmatic patients (Mean (SD) age 34 (6.4) years, mean 
FEV 1 85 (12.5) % predicted) were studied. All were taking inhaled short acting 
B2  agonists and 7 of the 8  regular inhaled corticosteroids. Inhaled B2  agonists 
were withheld for 6  hours prior to each visit, while corticosteroid therapy 
continued unchanged.
Patients attended the laboratory on 2 separate study days. A 24 hour collection of 
urine was obtained prior to each visit as an indirect means of assessing dietary 
sodium intake.
On arrival, 2 indwelling cannulae (Venflon®, Viggo, Helsingborg, Sweden) were 
inserted into forearm veins for the purposes of blood sampling and administration 
of the intravenous infusion. Patients were asked to rest for a period of 20 minutes, 
following which blood pressure and baseline spirometry were recorded. Thirty 
mis of venous blood was withdrawn for estimation of baseline plasma ANG 11 
levels. Each patient then received either ANG II (2, 4 and 8  ng/kg/min in 
increasing increments at 30 minute intervals) or placebo (5% dextrose). This was 
delivered intravenously by means of a 50 ml syringe driver (Perfusor® Secura E, 
B Braun, Melsunger AG). At the end of each 30 minute infusion period 
spirometry was measured (best of 3 readings) and blood withdrawn at the same 
time points for estimation of plasma ANG II. Patients remained semi-recumbant 
for the duration of the study. Oxygen saturation was monitored continuously 
throughout the study period.
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The study was approved by the Glasgow West Ethical Committee and informed 
consent was obtained from all participants. Subjects with known hypertension or 
taking regular diuretic therapy were excluded.
Drugs were prepared in the sterile unit of our pharmacy and administered 
according to a randomised, double blind crossover study design.
Measurements
Blood pressure - measured using a semi-automatic sphygmomanometer 
(Dinamap®, 1846 FX vital signs monitor; Critikon, Berkshire, UK), and the mean 
of 3 readings at each time point recorded.
Plasma ANG II - see Chapter 2.4, Hormone assays 
FEV 1 - see Chapter 2, Lung function
Oxygen saturation - pulse oximeter and finger probe (Ohmeda Biox 3700E, 
Ohmeda, Louisville, USA)
24 hour urinary sodium - see Chapter 2.7
Statistical analysis
Comparison of baseline values and the significance of changes in these at each 
time point was by one way analysis of variance, corrected for multiple 
comparisons.
We accepted p values below 0.05 as significant.
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8.3 RESULTS
1. Plasma ANG II
At 0, 30, 60 and 90 mins mean (SD) plasma ANG II levels were 12.4(5.3), 
25.1(4.0), 55.9 (10.2) and 121.3(20.2)pg/ml respectively after infusion of ANG II 
(2,4 and 8 ng/kg/min), and 12.8 (7.9), 12.2 (8.0), 11.1(6.9) and 11.5 (6.3)pg/ml 
after infusion of placebo (fig 8 .1).
2. Blood pressure and heart rate
Blood pressure did not change significantly during infusion of placebo. However 
following infusion of ANG II there were significant rises (p<0.05) in both systolic 
(fig 8.1) and diastolic levels. There were no significant changes in heart rate 
during infusion of placebo or ANG II (data not shown).
3. FEVl
There was no significant difference between baseline FEV ] on either study day. 
Mean (SEM) baseline values of FEV i were 2.55 (0.64) and 2.63 (0.34) litres prior 
to infusion of ANG 11 and placebo respectively. A significant bronchoconstrictor 
response to ANG II was observed at 60 and 90 minutes, with a mean (SEM) fall 
in FEVl from baseline values of 0.18 (0.03) and 0.34 (0.13) litres or 7.8 (2.02) 
and 12.4 (3.3) % respectively, compared to 0.02 (0.09) and 0.01 (0.09) litres or 
0.3(1.3) and 0.6 (1.2)% after placebo (fig 8.1). In addition, 5 out of 8  patients 
reported cough or chest tightness during the final infusion period.
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4. Oxygen saturation.
Mean (SEM) baseline oxygen saturation was normal on each study day [97.5 
(0.3)% prior to infusion of ANG II and 97.5 (0.2)% before placebo]. Oxygen 
saturation did not alter significantly during either infusion of placebo or ANG 11 
(data not shown).
5. 24 hr urinary sodium
There were no significant differences between 24 hour urinary sodium 
concentrations on either of the study days. Mean (SEM) 24 hr urinary sodium 
values were 178 (25.2) and 145 (2 1 .2 ) mmol/24hr prior to infusion of ANG 11 and 
placebo respectively.
Raw data for this chapter is included in the Appendix [tables 26A-28A].
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Fig 8.1 The effect of intravenous ANG II on systolic blood pressure (BP) and 
FEV i in asthmatic subjects [n==8 ]. Results as mean (SEM) absolute change (ANG 
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8.4 DISCUSSION
Recently, ANG II has been shown to potentiate vagally mediated contraction of 
rabbit airway smooth muscle through the activation of prejunctional receptors 
(126) thereby suggesting that it may have bronchoconstrictor activity in the 
human airway. In this study we have demonstrated that ANG II causes 
bronchoconstriction when administered intravenously to mild asthmatic patients. 
This effect occurs at pharmacological and pathological plasma levels of ANG 11, 
as the range of plasma levels obtained during the infusion occur after mutiple high 
doses of nebulised 6 2  agonists (Chapter 4 and 5) and during acute attacks of 
asthma (Chapter 3).
The exact mechanism of bronchoconstriction by ANG II is uncertain, but 
probably involves a direct effect of ANG 11 on airway smooth muscle similar to 
its vasoconstrictor action on vascular smooth muscle (102). These actions of ANG 
II are known to be mediated by the interaction of the hormone with specific, high 
affinity receptors in the plasma membrane of its target cells (165,166). Recently 
the development of specific ANG II receptor ligands has led to the identification 
of at least two different ANG II receptor subtypes, which mediate their action 
through different signal transduction mechanisms. Most of the actions of ANG II, 
including vascular smooth muscle contraction, are mediated via the AT l receptor 
(167), and it is likely that bronchial smooth muscle constriction also involves the 
same receptor subtype. This is a classical membrane protein which transmits 
ANG II actions via a G-protein linked pathway (Chapter 1.4.4), stimulating the 
enzyme phosphodiesterase which leads to the formation of the second messengers 
inositol triphosphate (IP3 ) and diacylglycerol (DAG). When vascular smooth 
muscle AT i receptors are activated, it has been proposed that increased release of
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calcium from the sarcoplasmic reticulum occurs via the formation of IP3  and also 
directly from G-protein-gated calcium channels (109). Such increased release of 
calcium results in increased vascular smooth muscle contraction and tone. As the 
effect of ANG II on bronchial smooth muscle has not been previously described, 
we can only speculate at this stage that the likely mechanisms will resemble those 
occuring in vascular smooth muscle.
The mechanism of bronchoconstriction by ANG 11 could also involve the release 
or potentiation of other mediators of bronchoconstriction. For example, ANG II 
has been shown to increase prostaglandin production under a varietv of 
circumstances (168) and can release platelet activating factor from cultured 
human endothelial cells (169). In addition, ANG 11 has also been reported to 
potentiate the pressor effects of endothelin -1 (itself also a potent 
bronchoconstrictor) (170). Another possible mechanism of airway smooth muscle 
contraction is by a reflex increase in vagal tone secondary to the rise in blood 
pressure that occurs during infusion of ANG II. However, against this theory is 
our finding that heart rate did not increase in our study.
In summary, this study is the first report of a bronchoconstrictor action of ANG 11 
in asthma. Since the range of plasma levels of ANG II achieved during the 
infusions are comparable to those found in acute severe asthma, it is possible th;il 
in some individuals this hormone may be contributing to a proportion of the 
bronchoconstriction in acute severe asthma.
CHAPTER 9
THE EFFECT OF ANGIOTENSIN II ON 
METHACHOLINE INDUCED BRONCHOCONSTRICTION 
IN VITRO AND IN VIVO
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9.1 INTRODUCTION
In a number of tissues, pre-treatment with ANG II can uncover or enhance 
contractions evoked by other agonists, for example, in rabbit saphenous artery, 
(i2 -adrenoceptor-mediated contractions are enhanced in the presence of low 
concentrations of ANG 11 (171). In addition ANG II has been shown to potentiate 
vagal-mediated contractions of rabbit trachea, probably by pre-junctional 
stimulation of acetylcholine release (126).
We have recently observed elevated plasma ANG II levels in patients with acute 
severe asthma (Chapter 3) and in the previous chapter have also shown that when 
mild asthmatic patients receive this hormone intravenously at doses which evoke 
similar plasma levels of ANG II to that observed in acute asthma, it causes 
bronchoconstriction. The mechanism of action of ANG II in causing this 
contraction is as yet unknown and may involve either a direct action on airway 
smooth muscle, or perhaps modulation of the effects of other mediators of 
bronchocon stri cti on.
In this present study, we firstly examined the direct effects of ANG II in vitro on 
human bronchial smooth muscle. We also investigated the ability of ANG II to 
interact with the bronchoconstrictor, methacholine. This study was then extended 
to examine in vivo the ability of ANG II to modulate bronchoconstriction evoked 
by methacholine in patients with mild asthma, where these patients were known 
to exhibit hyperresponsiveness to methacholine.
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9.2 MATERIALS AND METHODS
In vitro
Tissue Collection and Preparation.
Macroscopically normal human bronchial tissues (3rd to 6 th order) were 
obtained from patients undergoing thoracic surgery for bronchial carcinoma. 
Tissues were dissected free of connective tissue and fat and stored ovemighl at 
in oxygenated Krebs-Henseleit solution of the following composition (mM), 
NaCl 118.4, KCI 4.7, CaCl: 2.5, MgSO^ 1.2, NaHCOi 24.9, KH2PO4 1.2 and 
glucose 11.1. Published data has shown that overnight storage of this tissue does 
not alter its reactivity (172).
Measurement of Contractile Responses
Contractile responses were measured from rings of human bronchi (3-5mm) in 
vertical organ baths ( 1 0 ml) at 37 ± 0.5*^C in oxygenated (95% O2 , 5% CO2) 
Krebs-Henseleit solution. Tension (2g) was applied via two platinum wires into 
the lumen. One wire was anchored and the other attached to a force displacement 
transducer (Grass FT03T). Tissues were allowed to equilibrate for 2h, during 
which time applied tension was readjusted to the initial level. Concentration 
response curves were constructed to ANG II to ascertain the threshold fen 
contraction to this hormone. In a subsequent set of experiments, concentration 
response curves were constructed to methacholine in the presence and absence of 
ANG II (lO^M). Drugs were added directly to the organ bath and ANG II w as 
added I5min before methacholine concentration-response curves.
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In vivo 
Patients
7 mild asthmatic patients (3 female) were recruited from the outpatient clinic, 
mean (SD) age 26.8(8) years, mean (SEM) FEVl 82.1 (9.4)% predicted. All 
patients demonstrated at least mild bronchial hyperreactivity to inhaled 
methacholine, according to the method of Cockroft et al (133). All patients were 
taking inhaled short acting B2  agonists as required in addition to regular inhaled 
corticosteroids. None were on long acting inhaled (32 agonists or oral 
theophylline. All patients were otherwise in good health, in particular, none had a 
history of hypertension, nor were on diuretic therapy.
For the purposes of each study visit, inhaled 132 agonists were discontinued for at 
least 8  hours prior to attendance, but inhaled corticosteroids continued 
unchanged.
The study had the approval of the Glasgow West Ethical Committee and 
informed, written consent was obtained from each patient.
Study design
A randomised, double-blind study design was employed. At an initial screening 
visit the individual dose of methacholine required to cause a 2 0 % fall in their 
FEVl was determined (ie the PC20)- Bronchial reactivity to methacholine was 
determined using methods previously described (Chapter 2.3). Thereafter, 
patients attended the laboratory on 3 separate study days. At each visit, baseline 
FEY 1 (the best of 3 readings) was measured by dry wedge spirometer 
(Vitalograph, Buckinghamshire, UK), and blood pressure recorded.
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An intravenous cannula (Venflon ®, Viggo, Helsingborg, Sweden) was inserted 
into a forearm vein followed by a 20 min rest. A baseline blood sample was 
obtained for estimation of plasma ANG ÏI. Patients then received an intravenous 
infusion of placebo (5% dextrose) or ANG II (1 or 2 ng/kg/min) for a period of 
40 min. These doses were chosen as being below threshold for 
bronchoconstriction in a previous study (Chapter 8 ). The drugs were 
administered by 50ml syringe driver (Perfusor Secura E, B B Braun, Melsunger 
AG, Germany). A second blood sample was obtained (25 min from 
commencement of infusion) from the contralateral arm for estimation of plasma 
ANG II and the FEV i was recorded. While the intravenous infusion still 
continued, patients then received a methacholine challenge using the methods 
previously described (131,132), to determine the PC20- Following completion of 
the methacholine challenge, a final blood sample was withdrawn from the 
contralateral arm for plasma ANG II measurement and the intravenous infusion 
was discontinued. The effect of methacholine was then rapidly reversed with 
inhalation of nebulised salbutamol.
Blood pressure was monitored at 15 minute intervals and patients remained semi- 
recumbent for the duration of the study.
Measurements
Blood pressure - measured by semi-automatic sphygmomanometer (Dynamap, 
1846 FX Vital Signs Monitor, Critikon, Berkshire, UK) and the mean of 3 
readings recorded at each time point.
Plasma ANG II - see Chapter 2.4 , Hormone assays.
Drugs - see Chapter 2.8
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Statistical analysis
Statistical significance between data samples in the in vitro studies was tested by 
two-way ANOVA. Statistical difference between pD% values was by Student's l- 
test. In the in vivo studies, differences between placebo and active days was by 
Student's t-test with subsequent Dunnett test. A probability level of p<0.05 was 
considered significant. Number of observations (n) refers to the number of 
patients tested or from which tissue was obtained.
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9.3 RESULTS
In vitro studies
ANG II produced small (<0.25 g wt maximum), concentration-dependent 
contractions of human bronchi, with the threshold for contraction occurring 
between 3x10^ and 3xlO'^M. Pre-incubation with ANG II (lO'^M) evoked 
contraction in only two tissues and in those cases the level of contraction was 
less than 0.1 g wt (compared with control maximum contraction of 2.5-4.5 g wt 
with methacholine (3xl0 “^ M)). This concentration of ANG II however 
significantly (p<0.001) enhanced contractions to methacholine. This did not 
manifest itself as a shift in pD% values (pD2  represents -log EC 5 0 , the 
concentration of drug producing 50% maximal response) but rather as an 
increase in the magnitude of contractions evoked at concentrations of 
methacholine above lO^M. The maximum response was increased by 39.1% in 
human tissues [n=6 ] (Fig 9.1).
In vivo studies
There was no significant difference between baseline FEV ] (mean baseline FEVi 
(SEM) were 2.98(0.4)1, 2.8(0.4) and 2.9(0.3) prior to placebo, ANG II
I ng/kg/min and ANG II 2 ng/kg/min respectively).
After infusion of ANG II (1 or 2 ng/kg/min) and prior to methacholine challenge, 
there was no significant change in baseline FEV j values (Student's t-test). (mean 
baseline FEVi (SEM) were 2.8(0.4)1, 2.74(0.4) and 2.96(0.3) after placebo, ANG
II 1 ng/kg/min and ANG II 2ng/kg/min respectively). The PCoo for methacholine
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(expressed as geometric mean with range) after placebo infusion was 3.09 (1.15- 
6.0) mg/ml. After infusion with ANG II 1 ng/kg/min, this decreased to 2.14(0.85- 
3.8) mg/ml, although this did not reach statistical significance. In 6  out of 7 
patients, ANG II 2ng/kg/min potentiated the effect of inhaled methacholine. 
There was a significant (p=0.006) decrease in PC20 compared to placebo 
(geometric mean 1.2 (0.45-2.08) mg/ml) (Fig 9.2). Plasma ANG II 
concentrations were measured at baseline, prior to and on completion of each 
infusion. Results [mean (SEM)] were; 9.2(1.8 ), 9.5(2.0) and 9.9(1.8)pg/ml after 
placebo, 5.1(1.2), 16.2(0.9) and 27.3(5.2) pg/ml after ANG II 1 ng/kg/min and 
6 .0 ( 1 .5), 32.9(5.1 ) and 37.7(9.5) pg/ml after ANG II 2 ng/kg/min.
Blood pressure did not alter significantly during ANG II infusion (data not 
shown), and patients did not report any adverse symptoms.
Raw data for this chapter is included in the Appendix [tables 29A-31A].
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Fig 9,1 Concentration-response curves evoked by methacholine (10’'^- 3xlQ-^M) 
alone (# )  or in the presence of ANG II 10"^  M (Q ). ANG II produced a small 
contraction in only two tissues, however a significant (p<0 .0 0 1  by two-way 
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Fig 9.2 Individual PC20 values for methacholine (mg/ml) after placebo infusion 
(5% dextrose) and after IV infusion with ANG II 1 ng/kg/min or ANG II 
2ng/kg/min in mild asthmatic patients. ANG II I ng/kg/min produced an 
insignificant fall in PCoq-
However, ANG II 2ng/kg/min potentiated the effect of inhaled methacholine in 6 
out of 7 patients resulting in a significant decrease of PC20 compared to placebo,
p=0.006.
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9.4 DISCUSSION
The presence of ANG II in subthreshold concentrations markedly enhanced 
contractions evoked by the cholinergic agonist methacholine both in vitro in 
human bronchial smooth muscle and also in vivo in mild asthmatic patients. 
Furthermore, the potentiating effect of ANG II occured at doses which did not 
themselves cause bronchoconstriction. The levels of ANG II used in vitro were 
higher than occurs in the plasma of normal subjects (2-3x10^^(141). However 
local levels in the airway may not match the general plasma level, and in 
addition, in conditions such as acute severe asthma (Chapter 3) or severe 
congestive cardiac failure (173) ANG IT levels can be markedly elevated. Jn vivo, 
the circulating levels of ANG II produced were similar to those seen during 
exercise (174). Thus the potentiating action observed with ANG II on airway 
responsiveness is likely to have important effects on airway function at both 
physiological and pathological circulating concentrations of this hormone.
The means by which ANG II may potentiate bronchoconstriction is unclear, 
although a number of possibilities exist. Yamawaki and colleagues demonstrated 
in rabbit trachea that ANG II potentiated contractions evoked by electrical field 
stimulation, by increasing acetylcholine release (126). This occurred in the 
absence of any change in baseline tone evoked by ANG II alone. It is unlikely 
that reflex changes in vagally-mediated tone account for this action of ANG II in 
the present study, as blood pressure and heart rate were unaltered in the subjects 
during ANG II infusion. In addition, in the present study, in vitro, we have 
demonstrated a post-junctional effect of ANG II in potentiating methacholine-
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evoked contractions. The possibility therefore exists that ANG II may act both 
pre- and post-junctionally to facilitate bronchoconstriction.
Other means by which ANG II may enhance bronchoconstriction include the 
release of potential spasmogens such as endothelins (175), platelet activating 
factor (169), or arachidonic acid metabolites (168).
It has previously been described that ANG II evokes bronchoconstriction when 
present in higher concentrations, such as occurs in acute severe asthma (Chapter 
8 ). It now seems likely that the presence of relatively low concentrations of this 
hormone may result in paradoxically large constrictions by potentiating other 
mediators of bronchoconstriction. This may be of clinical importance not only 
during acute attacks of asthma, but also in patients with exercise-induced asthma 
where ANG II levels are also elevated (own unpublished observations). In 
adddition our findings may be of relevance to patients receiving high dose 
nebulised 8 2  agonists since plasma ANG II levels comparable to those in the 
present study have been observed in mild asthmatics given nebulised salbutamol 
(Chapters 4 and 5).
In conclusion, ANG II potentiates methacholine-evoked bronchoconstriétions, 
both in isolated human bronchi and in mild asthmatic patients. This may 
represent an important mechanism by which levels of ANG II which have little 
direct activity may produce substantial changes in airway tone. The mechanism 
for this interaction has yet to be elucidated.
CHAPTER 10
CONCLUSIONS
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This series of studies is the first to document activation of the renin-angiotensin 
system (RAS) in acute severe asthma and to report that the hormone ANG II not 
only has direct bronchoconstrictor effects on the human airway, but can also 
potentiate the bronchoconstrictor response to other mediators such as 
methacholine. These new observations are exciting and although this area of 
research is still in its preliminary stages, our findings raise the possibility that 
ANG II may play a role in the pathogenesis of asthma.
The initial studies were designed to identify possible stimuli to the RAS in acuîc 
severe asthma. Our results suggest that elevation of plasma renin and ANG 11 in 
acute asthma is likely to be a multifactorial phenomenon, although further work 
on this aspect is required. Hypoxia is unlikely to be activating the RAS in acute 
asthma, and the small elevation of haematocrit on admission reflecting a degree of 
haemoconcentration does not explain the prolonged elevations of renin and ANG 
II that persisted until day 5 after admission. There may be a minor effect of 
increased sympathetic drive in some patients with acute severe asthma, although 
[unlike the results of Ind et al (130)] there was no consistent increase in plasma 
adrenaline and noradrenaline in most of our cases. There is no doubt, how ever, 
that inhaled high dose 8 2  agonist therapy causes activation of the RAS , and we 
have confirmed this finding in several studies (Chapters 4, 5 and 6 ). A wide range 
of plasma renin and ANG II levels was noted in patients with acute asthma 
(Chapter 3) and although the reason for this variation is unclear, we suggested it 
could be the result of individual differences in factors influencing the RAS.
Several studies could be devised to extend this observation. Since it is known that 
patients admitted to hospital with acute asthma show wide variations in 
circulating salbutamol and terbutaline concentrations, with some having marked!}
114
elevated plasma levels of (3 agonist (153) it would be useful to measure individual 
plasma salbutamol levels on admission in acute severe asthma and detennine 
whether any correlation exists between B agonist levels and circulating renin and 
ANG n  concentrations. The role of allergen exposure, an event which is 
associated with mediator release from mast cells, is also unclear. Inflammatory 
mediators such as mast cell chymotryptases and neutrophil proteases released 
during an acute attack of asthma could cause a rapid formation of ANG II by an 
ACE independent pathway (66,131). This could be further investigated by 
measuring circulating inflammatory mediators such as plasma histamine or 
tryptase in venous blood in patients admitted to hospital with acute severe asthma, 
and determining whether these levels also correlate with those of plasma renin and 
ANG II. It might also be useful to examine whether allergen-induced early 
asthmatic responses which are associated wnth mast cell mediator release cause 
elevations in circulating ANG II levels.
Currently there is interest in the existance of polymorphism in the human ACE 
gene, with the DD genotype correlating with increased risk of myocardial 
infarction, perhaps as the result of increased local generation of ANG II in the 
coronary circulation (122). It is intriguing to speculate that if this were also the 
case in our asthmatic patients, then those who exhibit such polymorphism could 
have increased circulating levels of ACE, and resultant greater elevations in 
circulating ANG II levels in acute severe asthma and after high dose 8 2  agonists. 
Determination of the ACE genotype in each of these groups of asthmatic patients 
would be an interesting future exercise.
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The potential role of ANG II in exercise-induced asthma also warrants further 
studies. The RAS is known to be activated by exercise. Hespel et al have 
described an increase in plasma renin in normal volunteers follow ing exercise on 
a bicyle ergometer (72) and Kosunen et al reported marked increases in plasma 
renin and ANG II in male athletes after running exercise (174). We have also 
noted that asthmatic individuals have elevated plasma ANG II levels in response 
to graded exercise testing [mean (SEM) increase in ANG II of 22.6 (4.7)pU/ml 
from baseline, n=9] (own unpublished observations). As similar plasma levels of 
ANG II can potentiate bronchoconstriction (Chapter 9), then the possibility exists 
that ANG II may contribute to bronchoconstriction in exercise-induced asthma. 
The exact mechanism of exercise-induced asthma is currently an area of much 
research. One hypothesis is that the airway narrowdng in this condition is the 
result of theiTual effects of water loss, with increased osmolarity of airway surface 
fluid (176). This effect is known to increase mediator release from human mast 
cells which cause bronchial smooth muscle contraction (177). The finding that 
sodium cromoglycate, a drug known to inhibit the release of mast cell mediators 
(178), can reduce exercise induced asthma, has added support to the view that 
mast cell mediator release plays a contributory role. Future studies should 
examine whether there is an exaggerated plasma ANG II response to exercise in 
asthma compared to normal individuals and also whether pre-treatment of 
asthmatic patients with an ANG II antagonist (such as losartan) can attenuate 
exercise-induced asthma.
The finding that ANG II is elevated in the plasma in patients with acute asthma 
may be of clinical importance for several reasons. Firstly, at similar plasma levels 
we have demonstrated that this hormone causes bronchoconstriction in vivo and at
16
subthreshold doses it can also potentiate bronchoconstriction, both in vitro and in 
vivo. This suggests that ANG II is likely to be contributing to bronchoconstriction 
during an acute attack of asthma, and perhaps more importantly, may be 
enhancing the effects of other mediators of bronchoconstriction, even when 
present in very low/ concentrations itself. Secondly, ANG H could have several 
other potentially adverse effects on the airway in acute asthma. It is known (o 
cause pulmonary vasoconstriction and hypoxaemia (179) which could contribute 
to ventilation-perfusion imbalance during an acute attack of asthma, or perhaps 
cause reduced clearance of inflammatory mediators. Other reported actions 
include increased vascular permeability in experimental animals (180), raising the 
possibility that in asthma, elevated levels of this hormone could contribute to the 
inflammatory response within the airway. ANG II can also influence 
inflammatory cell function by several mechanisms: It is known from in vitro 
studies to have suppressive effects on lymphocyte proliferation (181), chemotactic 
properties for mononuclear cells (182) and regulatory effects on macrophage Fc 
and C3b receptor function (183,184). The presence of angiotensins has also been 
documented in alveolar macrophages and peripheral blood monocytes (185), 
raising the possibility that they may have some functional importance. Thus, it is 
conceivable that many of these actions of ANG II could assume clinical 
significance during the inflammatory processes of acute asthma.
Circulating ANG II levels are also elevated in cardiac failure (173). It has been 
suggested that high levels of ANG II in this condition may exert a range of 
adverse effects on the cardiovascular system, including cardiac myocyte necrosis
(186), coronary vasoconstriction and left ventricular hypertrophy (113). It seems 
unlikely, however, that transient elevations of ANG II represent any serious risk
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to asthmatic patients with normal coronary circulation and left ventricular 
function. However, in the situation of severe hypoxaemia during acute severe 
asthma, more prolonged elevations of plasma ANG II, perhaps allied with 
electrolyte imbalance and B adrenergic stimulation, may be of greater 
significance. Finally, by acting directly on the adrenal cortex, ANG 11 increases 
the secretion of aldosterone ( 1 0 2 ), resulting in. sodium retention and potassium 
loss. High levels of ANG II may therefore exacerbate hypokalaemia, particularly 
during an acute attack of asthma when high doses of 8 2  agonist are used (see 
below). Thus, there are several mechanisms whereby the hormone ANG II could 
potentially cause adverse metabolic, pulmonary and cardiac effects in acute 
asthma. However, the exact clinical significance of these in patients with acute 
asthma is not certain.
Several investigations have questioned the safety of inhaled 8 2  agonist therapy in 
asthma (Chapter 1.2.1). In the 1960’s it was suggested that the introduction of 
inhaled isoprenaline might have contributed to an increase in deaths from asthma
(187) and more recently a particular cluster of asthma deaths in New Zealand has 
been linked to the introduction of the 8 2  agonist fenoterol in that country (50-52). 
The question of whether the apparent adverse effects of prolonged use of 8 
agonists is a class-specific effect of all 8  agonists, or is simply confined to 
fenoterol has not been satisfactorily resolved. It is currently thought that fenoterol 
is used at a particularly high dosage level compared to other 8  agonists such as 
salbutamol and its 8 2  adrenoceptor selectivity is only marginal (151). It may 
therefore have its adverse effects mediated via cardiac 8 % adrenoceptors thus 
contributing to its association with increased mortality. Another unwanted effect 
may be the hypokalaemia that occurs when 8 2  agonists reach the systemic
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circulation. This may in turn increase susceptibility to cardiac arrythmias, 
although there is little evidence to suggest that arrythmias occur in near-fatal 
asthma attacks in patients admitted to hospital (188). B agonists may also be 
associated with increased morbidity from asthma. Single doses of inhaled B2 
agonists are know/n to exhibit a protective effect against bronchial 
hyperreactivity, w^hich appears to be functionally separate from their 
bronchodilator actions (189,190). However, it is widely believed that tolerance 
(tachyphylaxis) develops to protection against hyperreactivity during repeated 
dosing, thereby resulting in increased frequency of use and consequently an 
exacerbation of adverse effects (191). There is also evidence that prolonged 
treatment with regular B agonists may cause a deterioration in disease control 
(55), although the exact mechanism remains unclear. Van Schayck et al recently 
showed that inhaled salbutamol given continuously versus on demand led to a 
small but significant decline in FEV j over a duration of 12 months although there 
w/as no difference in airway reactivity or symptom scores (55).
Could our own observations that high dose 6 2  agonists elevate plasma ANG II 
levels be of any relevance to the B agonist debate? Apart from the multitude of 
potentially adverse acute effects of ANG II described above, of more interest and 
perhaps significance are the mitogenic properties of ANG II. Angiotensin II 
causes vascular smooth muscle cell growth both in vitro and in vivo by increasing 
the expression of growth-promoting oncogenes c-fos, c-jun and c-myc, by 
mitosis, by an increase in cell size and by increased synthesis of extracellular 
matrix proteins (192). If such effects occured on airway smooth muscle as a result 
of generation of excess ANG II in the lungs by regular administration of high 
doses of B2  agonists, then this could be of importance in the long term by
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contributing to the development of airway smooth muscle hypertrophy (as occurs 
in chronic asthma) and hence a decline in lung function. Thus, it would be 
relevant to pursue this theory by examining whether ANG IÏ could be a growth 
factor for airway smooth muscle. Lindop et al have recently infused the thymidine 
analogue bromodeoxyuridine subcutaneously into rats via osmotic minipumps and 
confirmed an increase in DNA synthesis (as measured by uptake of 
bromodeoxyuridine into cell nuclei) in rat mesenteric resistance arteries, but not 
veins, in response to low dose subcutaneous infusions of ANG 11 (Dr G Lindop, 
personal communication). It would be relevant in a future study to employ similar 
techniques to examine the effect of ANG II on bronchial smooth muscle. If we 
could confirm that ANG II is also a growth factor for airway smooth muscle, then 
this would clarify the role of ANG II in the pathogenesis of asthma and would 
also strengthen our hypothesis that high dose B agonists could adversely affect 
asthma control as a result of elevating circulating ANG II levels.
Local renin-angiotensin systems exist in many tissues and all the components of 
the system have been shown to be present and functional in a large number of 
sites such as the heart, kidney and brain (106). However it is not yet known 
whether such systems exist in human airway. Renin secreting tumours of the lung 
have recently been described, strengthening the possibility that renin producing 
cells exist in the lung (193) and renin mRNA has been detected in rodent but not 
human lung (194). In view of the results of our clinical studies and biological 
properties of ANG II, the presence of a local RAS in human airways could have 
important implications for the pathogenesis of asthma, and clearly this possibility 
needs to be further explored. It is possible to measure angiotensin I and II in 
human lung by specific radioimmunoassay techniques, and ANG II receptors can
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be identified using autoradiography on airway tissue sections (Dr J McQueen, 
personal communication). In addition, sensitive methods are also available to 
detect renin mRNA (194) and immuno-reactive renin (195) in cells from human 
lung. It is interesting to speculate that if a tissue RAS does exist in the lungs as 
occurs in other tissues, then this may lead to high local levels of ANG II being 
generated, eg in response to inhaled high dose Bo agonists, with the prospect of 
local modulation of bronchial smooth muscle tone or, in the longer term, airway 
smooth muscle hypertrophy. In Chapter 5, where we examined the effect of 
nebulised and intravenous B agonists on the activity of the RAS, we hypothesised 
that if a local RAS existed in the airways then perhaps the more marked 
elevations in plasma renin and ANG II noted after the inhaled route of 
administration could be the result of stimulation of a local RAS, with spill-over 
into the systemic circulation.
The effects of ANG II on airway tone also warrant further investigation. It would 
now be relevant to begin to explore possible pathways whereby ANG II could 
cause bronchoconstriction in asthma. From previously known effects of ANG II 
on vascular smooth muscle, the most obvious mode of action is a direct effect on 
airway smooth muscle, but the possibility of other mechanisms, such an indirect 
vagally mediated action or perhaps even via the release of other mediators of 
bronchoconstriction such as endothelins, prostaglandins or leukotrienes, also 
exist. It is known that ANG II can influence the autonomic nervous system both 
centrally  and peripherally . Enhancem ent of peripheral adrenergic 
neurotransmission by ANG II has been demonstrated in man. For example. 
Moulds et al showed that physiological concentrations of ANG II in vitro could 
enhance noradrenaline-induced contraction of human palmer digital artery (196),
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and Struthers et al demonstrated an interaction at the postsynaptic level between 
noradrenaline and ANG IT, with subpressor doses of intravenous ANG 11 
augmenting sympathetically mediated vasoconstriction in normal volunteers 
(197). In addition to the interaction between ANG II and the sympathetic nervous 
system, there is also evidence to suggest a peripheral interaction of ANG II with 
the parasympathetic nervous system. Potter has described attenuation by ANG II 
of the bradycardic response to vagal nerve stimulation in the dog (198), an effect 
unaffected by B blockade. In vitro work has also shown that ANG II has no effect 
upon the response of isolated atria to acetylcholine (199) suggesting a presynaptic 
vagal influence of ANG II.
Recently, Yamawaki et al studied the effect of ANG II on cholinergic 
neurotransmission in rabbit tracheal segments in vitro (126). Cumulative 
administration of ANG II in concentrations of 1 0"*’ to 10^  M did not alter the 
resting tension, but did augment the contractile responses of the airway smooth 
muscle to electrical field stimulation in a concentration-dependent manner. This 
effect was attenuated by the ANG II receptor antagonist CK-2961. In contrast, 
muscle contraction induced by exogenous acetylcholine was not altered by ANG 
II (10'(^ M), thereby suggesting that the ANG Il-induced augmentation of 
bronchoconstriction is pre- rather than post-junctional, probably by stimulation of 
acetylcholine release from cholinergic nerve terminals. Although it w^ as widely 
known from previous studies that ANG II could enhance adrenergic 
neurotransmission, this was the first study to report facilitation of cholinergic 
neurotransmission by ANG II. Our own results in human airw/ay (Chapter 9) are 
in agreement with those of Yamawaki, in that ANG II produced little or no direct 
effect on bronchial smooth muscle tone. How ever, we have also demonstrated a
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post-junctional action of ANG ÎI in potentiating bronchoconstriction, thus raising 
the possibility that ANG II can act pre and post junctionally to facilitate 
bronchconstriction. Previous studies have shown that ANG II can also stimulate 
the release of arachidonic acid metabolites (168), amongst which the 
prostaglandins D 2  (2 0 0 ) and F 2 a  (2 0 1 ) and thromboxane A 2  (202) are known to
augment parasympathetic bronchoconstriction by enhancing the release of 
acetylcholine. In addition, Nally et al have recently demonstrated that ANG II can 
enhance contractions of bovine bronchi by endothelin-1 (203). This potentiating 
action of ANG II appears to involve the AT j receptor subtype, as demonstrated 
by the inhibition of this effect of ANG II by the AT l antagonist losartan.
Several studies could be developed to further examine the mechanism of ANG II 
induced bronchoconstriction in asthma. The effect of pharmacological blockers on 
ANG II induced bronchoconstriction should be investigated by pretreatment of 
the asthmatic patient with an ANG II antagonist such as losartan, inhaled 
ipratropium bromide (cholinergic mechanisms) or oral indomethacin (cyclo- 
oxygenase products) and administering ANG II in doses previously known to 
cause bronchoconstriction. Having previously demonstrated a potentiating effect 
of ANG II on methacholine-induced bronchoconstriction (chapter 9), further 
examination of the effect of ANG II on bronchoconstriction induced by other 
mediators such as histamine, is also warranted in order to attempt to disentangle 
the pathways involved in the interaction of ANG II with other agonists in asthma. 
Future studies should also be directed at investigating the intracellular 
mechanisms involved in the actions of ANG II on human airway smooth muscle. 
The effect of ANG II on second messengers such as cGMP, cAMP and I- 
( 1 ,4 ,5 )P3  during receptor-mediated activation could be measured in the organ
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bath after modulating airway tone with ANG TI alone and in the presence of 
agonists or electrical field stimulation.
A putative inflammatory mediator in asthma should fulfil certain criteria as 
recently outlined by O'Byrne (204). These criteria are, in effect, modifications of 
the original Koch’s postulates (205), a set of guidelines which w^ere used to 
identify a microbe as the cause of a particular disease. The development and 
application of these steps in 1890 by Koch to the demonstration of the tubercle 
bacillus as the cause of tuberculosis is considered to be one of the milestones of 
medical history (206). Such postulates have been altered on several occasions and 
are still being applied to the identification of new agents of infectious disease.
For an agent to be considered as an inflammatory mediator in asthma it is said that 
the mediator and its structure must firstly be identified and when administered 
(usually by inhalation) to asthmatic patients it should mimic the asthmatic 
response. If we apply these criteria to ANG II, our results so far have confirmed 
this to be the case using intravenous infusions of ANG II, but not yet by 
inhalation, and so a future study should examine the effect of inhaled ANG II on 
airway tone in asthma. Secondly, with assay measurements being available for the 
potential mediator, it should be possible to measure it during asthmatic responses. 
Elevation of ANG II in the plasma has been demonstrated in acute severe asthma 
(Chapter 3), but we should now aim to measure this hormone in the plasma during 
asthmatic responses induced, for example, by stimuli such as cold air or allergen. 
Thirdly, when antagonists of the mediator or its synthesis are available, they 
should be studied in clinical models of asthma. The use of ACE inhibitor drugs in 
asthma is complicated by the fact that ACE appears to play a role in the genesis 
and metabolism of mediators of bronchoconstriction eg bradykinin and
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prostaglandins, and captopril-related asthma has been previously reported (207). 
However, the recent availability of specific ANG II antagonists such as losartan 
should now allow us to begin to examine these agents in different types of 
experimental asthma. Only once these questions have been answered will it then 
be possible to address the most difficult question, namely whether the mediator 
antagonists or synthesis inhibitors are actually of any value in treating asthmatic 
patients.
In summary, the results of this thesis have begun to provide evidence for a 
putative role of ANG II as a mediator in the pathogenesis of asthma. We believe 
that our results are promising and warrant further studies in order to increase our 
understanding of the effects of ANG II on airway function in asthma. It is 
interesting to speculate that, in the future, specific pharmacological targetting of 
the ANG II receptor may form the basis of a novel approach to the treatment of 
certain types of asthma.
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